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Abstract 
 
  Lipopolysaccharide (LPS) is the glycolipid that comprises the outer leaflet of the Gram-
negative outer membrane (OM). Because it is essential in nearly all Gram-negative species, and 
because it is responsible for making these bacteria impervious to many types of antibiotics, LPS 
biogenesis has become an important area of research. While its biosynthesis at the cytoplasmic 
face of the inner membrane (IM) is well studied, the process by which it is removed from the IM, 
transported across the aqueous periplasmic compartment, and specifically inserted into the outer 
leaflet of the OM is only beginning to be understood. This transport process is mediated by the 
essential seven-protein LPS transport (Lpt) complex, LptA/B/C/D/E/F/G. The OM portion of the 
exporter, LptD/E, is a unique plug-and-barrel protein complex in which LptE, a lipoprotein, sits 
inside of LptD, a β-barrel integral membrane protein. LptD is of particular interest, as it is the 
target of an antibiotic in Pseudomonas aeruginosa.  
  Part I of this thesis investigates how the cell forms the two non-consecutive disulfide 
bonds that connect LptD‟s C-terminal β-barrel to its N-terminal soluble domain. These 
disulfides, one of which is almost universally conserved among Gram-negatives, are essential for 
cell viability. Here, we show that an intermediate oxidation state with non-native disulfide bonds 
accumulates in the absence of LptE and in strains defective in either LptE or LptD. We then iv 
 
demonstrate that this observed intermediate is on-pathway and part of the native LptD oxidative 
folding pathway. Using a defective mutant of DsbA, the protein that introduces disulfide bonds 
into LptD, we are able to identify additional intermediates in the LptD oxidative folding 
pathway. We ultimately demonstrate that the disulfide rearrangement that activates the LptD/E 
complex occurs following an exceptionally slow β-barrel assembly step and is dependent on the 
presence of LptE. 
  Part II describes work towards obtaining X-ray crystal structures of the LptD N-terminal 
domain and LptD/E complex. Expression construct and purification optimization enabled the 
production of stable LptD/E in quantities that make crystallography feasible. Numerous 
precipitants, detergents, and additives were screened, ultimately resulting in protein crystals that 
diffract to a resolution of 3.85 Å. 
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Chapter 1: Introduction 
 
1.1. Introduction 
The cell envelope that surrounds Gram-negative bacteria is a double membrane structure 
in which the cytoplasm is enclosed by a phospholipid inner membrane (IM) that is separated 
from an outer membrane (OM) by an aqueous compartment known as the periplasm. The 
periplasm contains peptidoglycan, a polymer network that helps determine the cell‟s shape and 
protects it from osmotic stress
1,2. The OM faces the extracellular space and acts as a barrier that 
protects the cell from factors such as antibiotics and hydrophobic small molecules, making 
Gram-negative bacteria generally more resistant to antibiotics than Gram-positive bacteria
3,4. In 
contrast to the IM, the OM is an asymmetric membrane in which the inner, periplasm-facing 
leaflet is comprised of phospholipid, while the outer, extracellular space-facing leaflet is 
comprised of lipopolysaccharide (LPS). LPS, a glycolipid that is essential in most Gram-negative 
species, is generally credited as the source of the OM‟s relative impermeability
3,4. The 
biogenesis of LPS begins with its synthesis in the inner leaflet of the IM and is followed by its 
translocation across the IM, subsequent maturation in the periplasmic leaflet of the IM, and 
transport from the IM, across the periplasm, to its final location in the outer leaflet of the OM. 
Transport across the periplasm is facilitated by the seven protein lipopolysaccharide transport 
(Lpt) complex, LptA/B/C/D/E/F/G.  
  This thesis focuses on the two proteins that comprise the OM portion of the Lpt complex, 
LptD and LptE. Chapter 2 describes the research that elucidated the oxidative assembly pathway 
for the OM LPS translocon, LptD/E, and this pathway‟s significance in LPS transport. Chapters 2 
 
3 and 4 describe the progress that has been made towards obtaining the X-ray crystal structures 
of individual domains of LptD and of the two-protein LptD/E complex, respectively. 
  This chapter provides an overview of what is currently known regarding the structure, 
function, and biogenesis of the OM. Transport and assembly of the protein components of the 
OM are discussed with an emphasis on the transport and assembly of β-barrel integral OM 
proteins (OMPs). This is followed by a discussion of LPS that addresses its structure, 
biosynthesis, translocation across the IM, tailoring in the periplasm, and ultimate transport to the 
OM outer leaflet. Specific attention is paid to the Lpt complex and its components.  
 
1.2. The outer membrane is an asymmetric permeability barrier 
  The primary function of the OM is to establish a permeability barrier that enables the cell 
to maintain favorable intracellular conditions even in harsh extracellular environments. While 
typical membrane bilayers are impermeable to polar solutes, the OM is additionally impermeable 
to lipophilic molecules
3. This property of the OM is attributed to LPS; in fact, the presence of 
LPS causes the OM to be approximately two orders of magnitude less permeable to lipophilic 
substances than an equivalent phospholipid (PL) membrane bilayer
5,6. The impermeability of the 
LPS-containing OM is due to its lack of fluidity. LPS contains numerous saturated lipid chains 
and is able to interact with neighboring LPS molecules via bridging divalent cations, forming a 
gel-like structure with very low fluidity
3.  3 
 
 
Figure 1. The general structure of LPS. Lipid A represents the membrane anchoring unit, which 
is connected to two monomers of Kdo to give the minimal form of LPS needed for viability, Re-
LPS. Kdo is connected to a heptose region to form the remainder of the inner core. The second 
heptose is connected to the outer core oligosaccharide, altogether known as Ra-LPS. Ra-LPS is 
connected to the O-antigen oligosaccharide by the outer core. Gal, D-galactose; Glc, D-glucose; 
Hep, L-glycero-D-manno-heptose; Kdo, 3-deoxy-D-manno-oct-2-ulosonic acid. 4 
 
  Lipid A, a β-1,6 glucosamine disaccharide that is phosphorylated at positions 1 and 4‟ 
and hexa-acylated via modifications at positions 2, 3, 2‟, and 3‟ (Figure 1), forms the lipidic 
portion of LPS that anchors it into the membrane. Two monomers of Kdo (3-deoxy-D-manno-
oct-2-ulosonic acid) are attached to position 6‟ of the glucosamine disaccharide to form the 
minimal unit of LPS that is necessary for Escherichia coli viability
7. Additional sugars are often 
present as core regions or as part of the highly variable O-antigen. The inner core region is 
composed of an essential Kdo region and a heptose region. Kdo2-Lipid A, without any additional 
saccharides, is also known as Re-LPS. The inner core is connected to the outer core, as described 
in Figure 1. LPS containing the core oligosaccharides, but not the O-antigen oligosaccharide, is 
known as Ra-LPS
7. The additional sugars of the core and O-antigen regions are not generally 
required for viability, but may help the cells to survive in certain environments
4. One proposed 
function of the variable O-antigen sugars is to evade recognition by the immune system
7, as LPS 
activates the innate immune system via toll-like receptor 4 (TLR4)
8,9. This property of LPS is 
also why it is commonly known as endotoxin.   
A defining feature of the OM is its asymmetry; its outer leaflet almost exclusively 
contains LPS while its inner leaflet is comprised of PL. This was first suggested by Mühlradt and 
Golecki in 1975 when electron microscopy (EM) of Salmonella typhimurium OMs labeled with 
ferritin-conjugated antibodies against LPS showed that the label was only present on the outer 
leaflet of the membrane
10. Shortly thereafter, Kamio and Nikaido reported that the head groups 
of phosphatidylethanolamine, a PL, were inaccessible to modification by either Bacillus cereus 
phospholipase C or cyanogen bromide activated dextran in whole S. typhimurium cells
11. Taken 
together, these results suggest that the outer leaflet of the OM exclusively contains LPS while the 
inner leaflet exclusively contains PL. Subsequent research, such as the observation that nearly all 5 
 
LPS in intact S. typhimurium cells can be oxidized by galactose oxidase, has further established 
the asymmetric structure of the OM
12.  
In addition to lipids, the OM contains two broad classes of proteins: lipoproteins and 
integral outer membrane proteins (OMPs). Lipoproteins are post-translationally modified at their 
N-termini with three lipid chains that anchor them to the membrane, and they exist only on the 
periplasmic surface of the OM
13. These proteins are known to be involved in binding to 
peptidoglycan
14, OM stability
15, and OM biogenesis
16. In contrast to lipoproteins, OMPs assume 
a β-barrel fold that is inserted into the OM and extends from the periplasm to the extracellular 
space. This fold consists of a number of amphiphilic β-strands that form a continuous β-sheet in 
which one β-strand at the end of the β-sheet curves back around to the other side of the β-sheet to 
form a cylindrical barrel such that all peptide backbone hydrogen bonds are internally satisfied. 
The amphiphilic nature of the individual β-sheets results in a β-barrel in which the exterior is 
hydrophobic and the interior is hydrophilic. OMPs can feature additional N-terminal and C-
terminal domains, extensive extracellular loops that connect their β-strands, and β-barrels that 
can vary in size from 8 to as many as 24 β-strands
17. These features enable OMPs to be quite 
diverse, even though they share the same general β-barrel structure. OMPs serve a variety of 
purposes which generally enable the cell to be selectively permeable in order to carry out cellular 
functions without compromising the protection afforded by the OM. Such functions include 
passive nutrient exchange, either by non-specific porins or by substrate specific channels such as 
maltoporin, secretion of proteins and other molecules, membrane biogenesis, and even active 
uptake of specific substrates such as iron and vitamin B12
3.  
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1.3. Outer membrane biogenesis 
  As discussed earlier, the outer membrane is a complex, asymmetric structure that is 
composed of LPS, PL, lipoproteins, and β-barrel OMPs. The assembly of the OM presents a 
challenge that the cell must overcome; since there is no source of energy in the periplasm, all 
OM components must be synthesized in the cytoplasm and subsequently transported to the OM. 
This is especially challenging because the components of the OM are amphiphilic and must cross 
the aqueous periplasmic compartment. In recent years, the protein systems responsible for the 
transport of lipoproteins, OMPs, and LPS have been identified and aspects of their mechanisms 
have been elucidated. At this point, however, it is unclear how PL is transported to the OM. No 
protein machinery has been identified as being responsible for its transport, although the 
conserved mla genes have been found to function in the retrograde transport of PL from the 
OM
18. The PL composition of the OM is different from that of the IM in that it is enriched in 
phosphatidylethanolamine and saturated fatty acids, which suggests selectivity in PL transport
19-
21. LPS, but not PL, transport continues in E. coli spheroplast cells, suggesting that the two 
processes either occur via separate pathways or have different requirements for transport
22. PL 
transport has also been shown to be bidirectional
23,24 and dependent on the proton motive force, 
but not ATP, protein, or lipid synthesis
25. Together, these observations suggest the existence of 
an undiscovered mechanism of PL transport.  
 
1.3.1. Lipoprotein trafficking to the outer membrane 
  Lipoproteins, like OMPs and soluble periplasmic proteins, are translated in the cytoplasm 
as pre-proteins with an N-terminal signal peptide that directs them for secretion through the IM, 
in an unfolded state, by the Sec translocon
26. After secretion, pre-lipoproteins are lipidated via a 7 
 
three-step process that is triggered by recognition of a lipobox consensus sequence located near 
the signal peptide cleavage site. First, the enzyme Lgt forms a thioether linkage between a 
molecule of diacylglycerol and the cysteine residue that will ultimately become the N-terminal 
most amino acid of the mature protein. Next, LspA removes the signal peptide, and then Lnt 
acylates the amino group of the N-terminal cysteine. The ultimate result is a mature lipoprotein 
that is anchored to the outer leaflet of the IM by three fatty acyl chains that are attached to the 
most N-terminal residue of the protein
27.  
Following maturation, lipoproteins can either be retained in the periplasmic leaflet of the 
IM or exported to the periplasmic leaflet of the OM. The sorting of lipoproteins is dependent 
upon the residues present at positions 2 and 3 following the N-terminal Cys at position 1
28,29. The 
most important factor for retention in the IM is the presence of Asp at position 2
28. Other amino 
acids in position 2 can also trigger retention of model substrates, but generally only Asp is found 
in E. coli proteins
27,30. Depending on its identity, the amino acid in position 3 can either act 
synergistically with Asp at position 2 to promote retention (such as Asp, Asn, Glu, or Gln) or 
antagonistically to promote trafficking to the OM (such as Lys and His)
31.  8 
 
 
Figure 2. Biogenesis of outer membrane lipoproteins and OMPs. OMPs and lipoproteins are 
both translated as pre-proteins in the cytoplasm that are secreted across the IM by the Sec 
translocon. OMPs remain unfolded following translocation and are carried by chaperone proteins 
across the periplasm, where they are assembled into the membrane by the BamA/B/C/D/E 
complex. Lipoproteins are inserted into the periplasmic leaflet of the IM following translocation. 
They are removed from the membrane by LolC/D/E and passed off to LolA, which chaperones 
them to LolB. LolB then catalyzes their insertion into the inner leaflet of the OM. 
The removal of mature lipoproteins from the IM and their subsequent transport and 
insertion into the OM is catalyzed by the essential five-protein Lol (localization of lipoproteins) 
system (Figure 2)
27. The first component of the system was identified following the observation 
that lipoprotein release from E. coli spheroplasts only occurs in the presence of concentrated 9 
 
periplasmic exacts. These results suggested that there was a soluble periplasmic factor that was 
necessary for the release of lipoproteins from the IM. This factor was identified to be LolA, 
which forms a water-soluble complex with lipoproteins in order to chaperone them across the 
periplasm
32. Following this work, it was noted that the LolA-lipoprotein complex could transfer 
lipoprotein into the OM but not the IM. This led to the identification of LolB, a lipoprotein that 
interacts with the LolA-lipoprotein complex in order to facilitate release of the lipoprotein from 
LolA and its insertion in the OM
33. It was also observed that LolA is capable of removing 
lipoproteins that are imbedded in the IM but not those imbedded in the OM, and its ability to do 
so was found to be ATP-dependent
34. This led to the identification of the LolCDE complex. 
These proteins form an ATP binding cassette (ABC) transporter with a stoichiometry of (1:2:1 
LolC:LolD:LolE)
35. LolD serves as the nucleotide binding portion of the transporter with LolC 
and LolE together forming the eight helix transmembrane portion of the transporter
27. LolCDE 
recognizes lipoproteins and hydrolyzes ATP in order to facilitate their removal from the IM and 
transfer to LolA. Reconstitution of the Lol system in proteoliposomes revealed that LolCDE was 
the protein factor that recognizes the second and third residues of the lipoprotein to determine 
whether to retain it in the IM or transfer it to LolA for transport to the OM
36. LolCDE also fails 
to accept incompletely matured lipoproteins
37,38. This system has been determined to be the 
general pathway used in E. coli for lipoprotein trafficking
39. 
The structures of LolA and LolB reveal that the two proteins share a similar hydrophobic 
pocket that is likely to bind the hydrophobic portion of lipoproteins
40. This has led to the 
proposal of a “mouth-to-mouth” model of transfer in which a predicted hydrophobic cavity in 
LolC aligns with the hydrophobic cavity in LolA in order to transfer the lipoprotein cargo from 
LolCDE to LolA. LolA subsequently aligns its hydrophobic cavity with that of LolB in order to 10 
 
transfer the lipoprotein to it
41. In terms of energy, the Lol pathway uses LolCDE to hydrolyze 
ATP in order to generate a high energy LolA-lipoprotein intermediate that can favorably donate 
its lipoprotein to LolB to form the lower energy LolB-lipoprotein complex. This effectively 
couples the energy of cytosolic ATP to the distal process of inserting lipoproteins into the 
OM
41,42. The downhill nature of this process also prevents the reverse process and ensures that 
lipoproteins are retained in the OM once placed there.  
 
1.3.2. Transport and assembly of β-barrel outer membrane proteins 
Like lipoproteins and periplasmic proteins, OMPs are translated in the cytosol as pre-
proteins that bear N-terminal signal peptides. As with lipoproteins, these signal peptides trigger 
secretion via the Sec translocon through an ATP driven process
26. Following translocation, the 
nascent OMP is released from the IM following cleavage of the signal peptide by a signal 
peptidase. The OMP is then kept in a folding competent state by association with a periplasmic 
chaperone, such as SurA, Skp, or DegP
43,44. SurA is thought to form a distinct pathway from 
Skp/DegP, which are thought to be more important for stress response and rescue of misfolded 
proteins
45,46. The nascent OMP is chaperoned to the outer membrane where it interacts with the 
β-barrel assembly machine (Bam complex), which folds and inserts the β-barrel of the OMP into 
the OM (Figure 2)
43. The Bam complex is comprised of five individual proteins, 
BamA/B/C/D/E, and is required for assembly of nearly all OMPs
43,47. BamA is an essential β-
barrel containing OMP that was initially implicated in β-barrel assembly when it was observed 
that its depletion in Neisseria meningitidis led to the accumulation of misfolded OMPs in the 
periplasm
48. Initial speculation that BamA was also involved in LPS transport was disproven
49,50 
and the observed effects of BamA depletion on LPS trafficking are thought to be due to the fact 11 
 
that LptD, an essential OMP required for LPS trafficking, requires BamA for proper assembly
51. 
It is worth noting that BamA and LptD are the only β-barrel proteins that are known to be 
essential in E. coli. BamA in Gram-negative organisms contains five polypeptide transport-
associated (POTRA) domains at its N-terminus and a β-barrel domain at its C-terminus
52. The X-
ray crystal and NMR structures of the POTRA domains have been solved and show that they 
adopt similar folds, each consisting of a single three-stranded β-sheet that is folded over by a pair 
of antiparallel helices
53,54. The crystal structure showed interactions between pairs of POTRA 
domains via interactions between edges of β-sheets, which led to the proposal of a β-strand 
augmentation mechanism of β-barrel assembly, whereby POTRA domains assist the folding of 
β-barrels by complementing the β-strands of the nascent OMP as they assemble into a barrel
53. 
Four lipoproteins, BamB, BamC, BamD, and BamE, join BamA in comprising the Bam complex 
in E. coli. Of these, only BamD is essential. BamA interacts with BamB via POTRA domains 2-
4 and with BamC/D/E via POTRA domain 5
43.  
Protein folding catalyzed by purified Bam components has been reconstituted in 
proteoliposomes. These studies revealed that the Bam complex functions much more efficiently 
when all four lipoproteins are present. It also revealed that no source of energy was necessary, 
just a soluble, chaperone-stabilized or urea-denatured OMP
55. Subsequent work has 
demonstrated that the reconstituted system can undergo multiple rounds of protein folding and 
that certain lipoproteins alone are sufficient to assemble BamA
56,57.  
The structure of BamA was recently reported, with the authors noting several features in 
the structure that suggest a mechanism for BamA-mediated β-barrel assembly
58. First, they 
observed an interior cavity that is exposed in one structure, but closed in another, suggesting two 
possible conformations that might occur during β-barrel assembly. They also noted that the 12 
 
exterior of the BamA β-barrel features a narrowed hydrophobic surface that is hypothesized to 
disrupt the membrane to facilitate β-barrel insertion. There is also a narrowed contact between 
the first and last β-strands of the β-barrel, which they suggest is a possible point at which the β-
barrel might open to allow access to the membrane. The significance of these observations has 
yet to be established, and the mechanism of the Bam complex remains an active area of research.  
 
1.3.3. Lipopolysaccharide biogenesis in the inner membrane 
Since LPS is essential in nearly all Gram-negative bacteria and unique to bacteria, its 
biosynthesis has strong potential as an antibiotic target. As a result, it has been extensively 
studied, is well understood, and has largely been reconstituted in vitro
7,59. Broadly speaking, the 
process begins in the cytoplasm with the synthesis of Kdo2-Lipid A and is followed by addition 
of the remaining core oligosaccharides. The nascent Ra-LPS is flipped into the periplasmic 
leaflet of the IM, where it is decorated with the O-antigen oligosaccharide, concluding its 
biosynthesis, before trafficking to the OM.  13 
 
 
Figure 3. The biosynthetic pathway of LPS biosynthetic intermediates Lipid X and UDP-diacyl 
GlcN. 
Kdo2-Lipid A is produced in the cytoplasmic leaflet of the IM in the multistep process 
described in Figure 3 and Figure 4
7. The first step in its biosynthesis begins with transfer of R-3-
hydroxymyristate onto UDP-N-acetylglucosamine (UDP-GlcNAc) in a thermodynamically 
unfavorable process catalyzed by LpxA
59-61. LpxC then hydrolyzes the acetyl group in a 
favorable process that constitutes the first committed step of LPS biosynthesis
61-63. Another R-3-
hydroxymyristate moiety is added to the newly revealed amine by LpxD to give UDP-2,3-
diacylglucosamine
64. In some portion of UDP-2,3-diacylglucosamine, the phosphoanhydride 14 
 
bond of UDP is hydrolyzed by LpxH to give the intermediate Lipid X (2,3-diacylglucosamine-1-
phosphate) and UMP (Figure 3)
65,66. Subsequently, a molecule of Lipid X and UDP-2,3-
diacylglucosamine are condensed by LpxB to form the β-1,6 linked glucosamine disaccharide 
that is characteristic of LPS
67. The resulting intermediate is phosphorylated by LpxK at the 4‟ 
position using ATP to give Lipid IVA
68,69. Lipid IVA is modified twice by WaaA, which utilizes 
two molecules of CMP-Kdo to add two units of Kdo to the 6‟ position of the Lipid IVA 
glucosamine disaccharide
70,71. LpxL and LpxM catalyze the final two acyl transfer reactions that 
yield Kdo2-Lipid A, the hexa-acylated species that forms the minimal LPS needed for viability. 
LpxL adds laurate to the β-hydroxyl group of the 2‟ lipid
72, and LpxM adds myristate to the β-
hydroxyl group of the 3‟ lipid (Figure 4)
73. It is worth noting that since these enzymes are 
selective for the Kdo2 containing intermediate, Lipid A is never actually formed as an 
intermediate during LPS biosynthesis, despite being the complete membrane anchoring unit. 
While Kdo is generally recognized as being required for cell viability, certain suppressor strains 
have been generated that can rescue Kdo-depleted E. coli, though these and other minimal LPS 
mutants tend to display OM defects and exhibit stress responses
74-76.  15 
 
 
Figure 4. Biosynthetic pathway of Kdo2-Lipid A beginning with intermediates described in 
Figure 3. 16 
 
 
  While Kdo2-Lipid A is sufficient for viability in E. coli, LPS typically features additional 
sugars in the form of a core oligosaccharide and O-antigen oligosaccharide. Like Lipid A 
biosynthesis, the installation of the core oligosaccharide occurs on the cytoplasmic leaflet of the 
IM, where it is carried out by a series of membrane-associated glycosyltransferases
77. In contrast 
to Lipid A, the core oligosaccharide tends to be less conserved. The inner core is more conserved 
than the outer core and typically contains Kdo and Hep (L-glycero-D-manno-heptose), while the 
outer core commonly contains D-glucose and D-galactose in addition to the types of sugars 
found in the inner core
77. The genes responsible for core oligosaccharide assembly are found in 
the gmhD, waaQ, and kdtA operons
78. The gmhD operon encodes the genes needed for synthesis 
and transfer of Hep
79. The kdtA operon encodes genes needed for Kdo installation
80. The waaQ 
operon encodes additional genes that are responsible for the synthesis and assembly of the outer 
core sugars
77. Like Ra-LPS, the precursors to the O-antigen oligosaccharide are synthesized on 
the cytoplasmic leaflet of the IM, where they are assembled by glycosyltransferases from sugar-
nucleotide substrates and anchored to the membrane by an undecaprenyl phosphate moiety
77. O-
antigen precursors are flipped to the periplasmic face of the IM by Wzx, where they are 
polymerized by Wzy and Wzz
81. The genes responsible for the synthesis, polymerization, and 
flipping of the O-antigen oligosaccharide to the periplasm are encoded by the rfb gene cluster
4. 
The gmhD operon also encodes the ligase, WaaL, that is responsible for the addition of the O-
antigen polysaccharide to Ra-LPS (core-Lipid A)
81,82. WaaL acts in the periplasm, following 
flipping of Ra-LPS from the inner leaflet of the IM.  
  Numerous modifications to both the sugar and lipid regions of Lipid A have been 
reported. Functions of these modifications include resisting cationic antimicrobial peptides, 17 
 
evading immune recognition, and adapting to stressful extracellular environments
77. These 
modifications are often mediated by the PmrA-PmrB two-component system, which regulates 
virulence and responds to stresses such as high Fe
3+ and low Mg
2+, or by the PhoP-PhoQ two-
component system, which also responds to low Mg
2+ and is involved in virulence
79,83-86. 
Activation of the arn operon ultimately results in the transfer of 4-amino-4-deoxy-α-L-arabinose 
onto the Lipid A 4‟-position phosphate
77,87-89. Modification of the phosphate group at the 1-
position with phosphoethanolamine is also triggered by the PmrA-PmrB two-component 
system
77. These modifications both aid in resistance to certain antimicrobial peptides and are 
implicated in virulence
90. The 1- and 4‟- phosphates are cleaved by phosphatases in some 
species, which is associated with virulence
91. A number of enzymes are known that modify the 
lipid portion of Lipid A via acylation, deacylation, and hydroxylation. PagP transfers a palmitate 
moiety to the β-position of the 2-position lipid chain, resulting in a hepta-acylated Lipid A 
derivative
92. PagL is a lipase that 3-O-deacylates Lipid A
93. LpxO introduces S-2-hydroxy 
modifications to the myristate attached to β-hydroxyl of the 3‟-myristate
94.   
  Following the synthesis of core-Lipid A, but prior to the addition of the O-antigen 
oligosaccharide, LPS is flipped from the inner leaflet of the IM to the outer leaflet of the IM. 
This process features a high activation barrier and is facilitated by the ABC transporter MsbA
95. 
MsbA was first reported as a multicopy suppressor of an LpxL temperature-sensitive mutant and 
lpxL deletion
96. Further studies observed that in LpxL temperature-sensitive mutants, hexa-
acylated LPS is predominantly observed at the OM even after several generations at a non-
permissive temperature. In these cells, however, significantly higher amounts of tetra-acylated 
LPS are observed at the OM when extra copies of msbA are present, establishing a role for MsbA 
in LPS transport
97. This suggests that extra copies of msbA suppress loss of LpxL function 18 
 
because MsbA is inefficient at transporting tetra-acylated LPS species. Subsequently, a 
temperature-sensitive mutant of MsbA was found to lead to accumulation of Lipid A in the 
cytoplasmic leaflet of the IM, as judged by its lack of modification by periplasmic enzymes, 
which firmly established that MsbA is the IM LPS flippase
95. MsbA was purified and its activity 
was reconstituted in proteoliposomes. In this assay, it was found that hexa-acylated species, such 
as Kdo2-Lipid A, stimulated MsbA activity, while tetra-acylated species, such as Lipid IVA, did 
not
98. This is consistent with the observation that MsbA is inefficient at transporting tetra-
acylated LPS species
97.  
    19 
 
 
Figure 5. Stereo view of the X-ray crystal structure of the MsbA homodimer in three 
conformations. MsbA exhibits large structure rearrangements between the nucleotide bound (A), 
open apo (B), and closed apo (C) states. Figure taken directly from Ward et al
99. Copyright 2007, 
National Academy of Sciences, USA. 
The X-ray crystal structures of MsbA from several related species were found to 
crystallize in a number of conformations that, when taken together, suggest that large structural 
rearrangements occur during the ATP binding and hydrolysis cycle (Figure 5)
99. MsbA from E. 
coli crystallized in an apo-state that is open to the cytoplasm. MsbA from Vibrio cholera 20 
 
crystallized in an apo-state that features a closed, cytoplasm-facing conformation. MsbA from S. 
typhimurium crystallized with bound AMPPNP in an outward facing conformation. These 
structures suggest a model in which LPS binding to MsbA‟s open, inward facing apo-state (as in 
Figure 5B) triggers a structural rearrangement in which the transmembrane domains come 
together to produce a closed, inward facing apo-state (as in Figure 5C). Subsequent nucleotide 
binding would then induce a conformational change that produces the outward facing 
conformation (as in Figure 5A) that would allow LPS access to the outer leaflet. Hydrolysis of 
the nucleotide would presumably allow the cycle to repeat
99. Extensive studies of MsbA using 
electron paramagnetic resonance (EPR) spectroscopy have proven consistent with this model and 
help validate the relevance of the crystal structures
100,101. 
 
1.3.4. Lipopolysaccharide biogenesis: transport to the outer membrane 
  Once fully mature and present at the outer leaflet of the IM, LPS must be transported 
across the aqueous periplasm to the outer leaflet of the OM, where it functions to establish a 
permeability barrier. This transport is facilitated by the trans-envelope Lpt complex (Figure 6), 
which is comprised of LptA/B/C/D/E/F/G, all of which are essential in most Gram-negative 
organisms, including E. coli.  21 
 
 
Figure 6. The trans-envelope Lpt complex removes LPS from the periplasmic leaflet of the IM 
and inserts it directly into the outer leaflet of the OM.  
  LptB2CFG are the IM portion of the Lpt complex, where they form an ABC transporter in 
which LptF and LptG provide the transmembrane domains and two molecules of LptB provide 
the nucleotide binding domains
102. LptC is a single pass transmembrane protein that contains a 
periplasmic OstA domain that is homologous to domains found in LptA and LptD. LptA is a 
soluble periplasmic protein that interacts with the OstA domains of LptC and LptD to create a 
periplasm-spanning bridge
103. LptD and LptE form a tight complex and represent the OM portion 
of the Lpt complex. LptD contains a soluble, N-terminal OstA domain and a membrane 
spanning, C-terminal β-barrel domain
104,105. LptE is a lipoprotein that forms a plug inside the 
LptD β-barrel
106.  
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1.3.4.1 Identification of the Lpt proteins 
  LptD, the first Lpt protein to be identified, was reported in 1989 by Sampson et al. 
following a genetic selection for mutations that increased outer membrane permeability and 
allowed large maltodextrins to cross the OM in the absence of the LamB maltoporin
107. One of 
the reported mutations, LptD4213 (Δ330-352), elicited a particularly strong phenotype that 
resulted in sensitivity to a variety of detergents and antibiotics. This work also established LptD 
to be essential in E. coli. Braun and Silhavy later showed that LptD depletion led to 
mislocalization of outer membrane proteins and lipids, establishing its role in envelope 
biogenesis
108. Bos et al. further refined the role of LptD to LPS biogenesis by showing that loss 
of LptD in N. meningitidis resulted in loss of LPS at the cell surface, as judged by PagL labeling 
and inaccessibility to extracellular neuraminidase
51. While most Gram-negative species require 
LPS for viability, it is not essential in N. meningitidis, which enabled its deletion by Bos et al.
109 
Other species in which LPS is not essential include Acinetobacter baumanii
110, Moraxella 
catarrhalis
111, and Helicobacter pylori
112. Wu et al. used affinity purification techniques to 
purify LptD, and in doing so, co-purified LptE. Depletion of either LptD or LptE prevented 
labeling of LPS by PagP, establishing that both proteins are essential for LPS transport
104. 
  LptA and LptB were first identified by random transposon mutagenesis as being essential 
in E. coli
113. Subsequent research revealed that genes encoded in the same locus as lptA and lptB 
were responsible for synthesis of Kdo, hinting at a role for LptA and LptB in OM biogenesis
114. 
Sperandeo et al. soon showed that mutants depleted of LptA and/or LptB are defective in LPS 
transport to the OM and proposed a model in which LptB is the nucleotide-binding domain of an 
ABC transporter that hydrolyzes ATP in order to remove LPS from the membrane and pass it to 
LptA
115. The observation that the lptA gene overlapped with another gene, lptC, led to the 23 
 
identification of LptC, and subsequent research confirmed that it was required for LPS transport 
to the OM
116.  
  Given that LptB was believed to form the nucleotide-binding domain of an ABC 
transporter, and since the single transmembrane helix of LptC is not sufficient to provide the 
transmembrane domains of an ABC transporter, it was known that at least one Lpt protein 
remained to be discovered. Using this knowledge, LptF and LptG were identified by a 
bioinformatics approach that scanned the genome of a Gram-negative endosymbiont, 
Blochmannia floridanus, for essential genes of unknown function
102. LptF and LptG were then 
shown to be essential for LPS transport and were proposed to be the missing transmembrane 
domains of the IM ABC transporter.  
 
1.3.4.2. The Lpt proteins form a trans-envelope complex 
  Following the identification of the seven Lpt proteins, questions remained concerning the 
mechanism of LPS transport. Of principal interest was the architecture of the system as a whole. 
Two primary hypotheses existed, one in which LptA acts as a periplasmic chaperone that binds 
LPS and shuttles it across the periplasm in a manner analogous to LolA‟s handling of 
lipoproteins, and another in which LptA forms a periplasmic bridge that connects the IM ABC 
transporter to the OM translocon, LptD/E, to form a continuous, trans-envelope complex
16. 
Several pieces of evidence initially suggested a trans-envelope model. First, it was observed that 
LPS transport continues in spheroplasts, while lipoprotein transport does not, which suggests that 
LPS transport does not occur via a soluble periplasmic chaperone like lipoprotein transport
22. 
Second, the elucidation of the LptA X-ray crystal structure revealed crystal contacts between 
neighboring molecules that form end-to-end stacked fibrils with a continuous hydrophobic 24 
 
groove running throughout (Figure 7)
117. This form of contact provided a mechanism by which 
LptA could form a periplasm-spanning bridge that could accommodate the movement of LPS. 
Given the homologous OstA domains found in LptD and LptC, it also provided a mechanism for 
how such a bridge could connect the IM and OM portions of a putative trans-envelope complex. 
When the X-ray crystal structure of the LptC OstA domain was solved, it revealed a β-jellyroll 
fold similar to that of LptA (Figure 8)
118. This supported the theory that LptA and LptC interact 
in an end-to-end fashion similar to that observed in the LptA crystal structure. 
 
Figure 7. The X-ray crystal structure of LptA reveals a β-jellyroll fold in which neighboring 
molecules form end-to-end stacked fibrils that feature a continuous hydrophobic groove. Figure 
taken directly from Suits et al
117. Copyright 2008, Elsevier.   
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Figure 8. The X-ray crystal structure of the LptC periplasmic domain shows a β-jellyroll fold 
similar to that of LptA. Figure taken from Tran et al
118. Copyright 2010, American Society for 
Biochemistry and Molecular Biology.  
  Chng, Gronenberg, and Kahne demonstrated in 2010 that all seven Lpt proteins can be 
co-purified by affinity purification using a His-tag on LptC, establishing that all of the Lpt 
proteins interact with one another. Using sucrose gradient fractionation, they were also able to 
show that all of the Lpt proteins co-fractionate to a distinct membrane fraction, termed OML, 
which contains both IM and OM components
119. From these data, it was concluded that the Lpt 
proteins form a membrane-spanning, trans-envelope complex. Direct interaction between LptC 
and LptA was also observed, supporting the trans-envelope model
120. Freinkman et al. further 
established the existence of the trans-envelope bridge and provided evidence that supported an 
end-to-end stacking model in which the OstA domains of LptC, LptA, and LptD interact in much 
the same way as was observed in the LptA crystal structure. By placing the photo-crosslinking 
unnatural amino acid p-benzoylphenylalanine (pBPA) at specific locations in LptA, LptD, and 26 
 
LptC, they were able to observe UV-induced crosslinks between LptA and LptC and between 
LptA and LptD that were consistent with the model shown in Figure 9
103.  
 
Figure 9. Proposed structure of the Lpt trans-envelope bridge. When pBPA is placed at the 
indicated positions in N-LptD, LptA, or LptC, UV-induced crosslinking can be observed 
between the mutagenized protein and its contact partner. The N-LptD structure is a predicted 
structure. Figure taken directly from Freinkman et al
103. Copyright 2012, American Chemical 
Society. 
 
1.3.4.3. Studies investigating the inner membrane complex, LptB/F/G/C   
Because of its enzymatic activity, the ATPase function of the IM ABC transporter is the 
most obvious target for inhibition of the Lpt complex. The ATPase activities of both LptB and 
LptB2FGC have been reconstituted in vitro and have proven useful in screening for LptB 27 
 
inhibitors
121,122.  The X-ray crystal structure of LptB was recently reported, and residues critical 
for catalytic activity and transmembrane domain binding were identified
123.   
Okuda, Freinkman, and Kahne were able to trap LPS transport intermediates on LptA and 
LptC using site-specific crosslinking facilitated by pBPA. They were able to show that multiple 
rounds of ATP hydrolysis are necessary to observe said crosslinking, demonstrating that the 
energy needed for LPS transport comes from ATP hydrolysis by the IM ABC transporter. From 
these data, they proposed a model in which LPS is pushed through the trans-envelope bridge in a 
continuous stream, powered by ATP hydrolysis
124.  
 
1.3.4.4. Studies investigating the outer membrane translocon, LptD/E 
  Further characterization of the LptD/E complex established that it exists as a stable 1:1 
complex that can be overexpressed and purified. It was found that LptD interacts with LptE via 
its C-terminal β-barrel domain, but that both the N-terminal and C-terminal domains are 
necessary for cell viability. Furthermore, it was shown that the LptD C-terminal β-barrel domain 
protects LptE from trypsin digestion, which led to the hypothesis that LptE is a plug that is 
situated inside of the LptD β-barrel
105. Other studies utilized pBPA-mediated site-specific 
crosslinking to further establish the plug-and-barrel model by showing that various positions on 
all sides of LptE make contact with LptD. One specific crosslink was determined to be to a 
predicted extracellular loop of LptD. Removal of this loop, LptDΔ529-538, results in an increased 
OM permeability phenotype similar to the one observed in LptD4213. These studies also led to 
the proposal of a direct insertion model of LPS insertion into the outer leaflet of the OM, 
meaning that LPS is never placed in the inner leaflet of the OM, but instead is transported 
directly from the LptD β-barrel lumen to the cell surface
106. 28 
 
  LptD in E. coli contains four cysteine residues at positions 31, 173, 724 and 725, and they 
were known to form disulfide bonds
108. Ruiz et al. performed an exhaustive characterization of 
the oxidation state of LptD; by constructing all possible combinations of single, double, triple, 
and quadruple mutations of cysteine to serine, and by using non-reducing SDS-PAGE to observe 
the disulfide bonds that form in each mutant in vivo, they were able to determine that mature 
LptD is fully oxidized and contains two intramolecular disulfide bonds between C31 and C724 
and between C173 and 725
125. Both of these disulfide bonds connect the N-terminal periplasmic 
domain to the C-terminal β-barrel domain, suggesting that they may play some role in orienting 
the two domains relative to one another. Ruiz et al. also established the essentiality of these 
disulfide bonds; neither individual disulfide is necessary for viability so long as at least one of 
the two is present
125. They also found that the periplasmic oxidase DsbA is important, but not 
absolutely required, for LptD oxidation, consistent with previous identification of LptD as a 
substrate for DsbA
125,126. They found no requirement for DsbC, a disulfide bond isomerase, in 
LptD oxidation, but noted that LptE depletion results in a loss of proper LptD oxidation. The 
same effect was not observed for LptF/G depletion, suggesting a specific role for LptE in the 
assembly of LptD
125.  
The lptE6 mutant allele, in which LptE amino acids 116-120 (YPISA) are mutated to 
YRA, was isolated during a screen for mutations that increase OM permeability. The lptE6 allele 
was found to interfere with LptD oxidation, and suppressor mutations to lptE6 were isolated in 
bamA and lptD; therefore, it was proposed that LptE must play some role in LptD assembly at 
the Bam complex
127. Similarly, suppressors to lptD4213 have been isolated in bamA and 
bamB
128,129. Taken together, these findings suggest that LptE and LptD interact together at the 
Bam complex during LptD/E biogenesis.  29 
 
  In 2010, a peptidomimetic antibiotic was reported whose target appears to be LptD in 
Pseudomonas spp. The antibiotic was found to crosslink to LptD in vivo; furthermore, resistance 
mutations were found to arise in the N-terminal domain of LptD. Specifically, tandem 
duplication of nucleotides 628 to 645, corresponding to duplication of amino acids 210-215 
(LRDKGM) were found to confer resistance to the drug (numbering refers to P. aeruginosa 
lptD)
130. Interestingly, this duplication lies immediately downstream of amino acids 207-209 
(GNV), which are three of the most highly conserved residues in lptD homologues. The 
mechanism of this antibiotic and the significance of this resistance mutation are not yet 
understood.  
 
1.4. Perspectives 
  Bacterial resistance to antibiotic drugs is an escalating problem that severely threatens 
our society
131. This issue is particularly pronounced in Gram-negative organisms for which 
treatments are already limited due to the relative impermeability of the OM. Consequently, the 
identification of new antibiotic drugs and antibiotic targets is imperative. Biogenesis of the 
Gram-negative outer membrane provides an attractive target because of its essential nature, the 
fact that its disruption causes sensitivity to otherwise ineffective drugs, and because of its 
accessible location at the cell surface. Several molecules have been identified that validate OM 
biogenesis as a drug target, such as inhibitors of LpxC
132,133, LptB
121,122, and the peptidomimetic 
drug believed to target LptD
130; however, our understanding of OM biogenesis is far from 
complete, and as such, there are still a number of open questions. Perhaps most striking is that 
we know virtually nothing regarding phospholipid trafficking to the OM, and while the 30 
 
molecular components involved in OMP and LPS trafficking have likely all been identified, the 
mechanisms by which they function are poorly understood.  
The remaining chapters of this dissertation focus on furthering our understanding of the 
biogenesis and mechanism of LptD/E. Chapter 2 documents research that led to the elucidation 
of the oxidative assembly pathway of LptD/E that culminates in a disulfide bond rearrangement 
that activates the LPS translocon. Chapters 3 and 4 document efforts to determine the X-ray 
crystal structure of the LptD/E complex. Chapter 3 details the more limited goal of obtaining a 
crystal structure for just the N-terminal, periplasmic domain of LptD, while chapter 4 chronicles 
the ongoing effort to obtain a crystal structure for the two-protein complex. As a whole, the 
research described herein has contributed to our knowledge of LPS transport and could 
ultimately help address questions regarding the mechanism by which LptD and LptE handle LPS 
and facilitate its insertion into the outer leaflet of the OM.  
   31 
 
 
Chapter 2: Disulfide Rearrangement Triggered by Translocon Assembly Controls 
Lipopolysaccharide Export 
 
This chapter is adapted from: Chng, S. S., Xue, M., Garner, R. A., Kadokura, H., Boyd, D., 
Beckwith, J., Kahne, D. Disulfide rearrangement triggered by translocon assembly controls 
lipopolysaccharide export. Science 337, 1665-1668, (2012). Reprinted with permission from 
AAAS. 
 
Collaborators: Shu Sin Chng, Mingyu Xue, Hiroshi Kadokura, Dana Boyd, Jonathan Beckwith, 
Daniel Kahne. 
 
2.1. Introduction 
  The essential, two-protein LptD/E complex forms the OM portion of the trans-envelope 
Lpt complex and exists as a unique plug-and-barrel arrangement in which the lipoprotein LptE is 
situated inside of the β-barrel domain of LptD
105,106,119. Additionally, the N-terminal periplasmic 
domain (amino acids 25-202; E. coli numbering) of LptD is connected to its C-terminal β-barrel 
domain (amino acids 203-784; E. coli numbering) by two long range, non-consecutive disulfide 
bonds between C31 and C724 and between C173 and C725
105,125. The plug-and-barrel 
arrangement, coupled with the interdomain disulfide linkages, likely presents a challenging 
protein-folding problem. It also remains unknown how the cell coordinates assembly of the 
LptD/E complex with the rest of the trans-envelope complex. To understand the assembly of the 
LptD/E complex, we investigated the biogenesis of LptD.  32 
 
  Such work is made possible by the fact that different disulfide-bonded states of LptD can 
be visualized and distinguished from one another using SDS-PAGE. Wild-type (WT) cells 
contain only fully oxidized LptD that contains the C31-C724 and C173-C725 disulfide bonds, 
hereafter referred to as [1-3][2-4]-LptD because the linkages exist between the first and third and 
between the second and fourth cysteine residues. [1-3][2-4]-LptD migrates more slowly than 
reduced LptD when analyzed by SDS-PAGE, and other disulfide-bonded species of LptD 
migrate at unique speeds
125.  
 
2.2. Results and Discussion 
2.2.1. Observation of a non-native disulfide-bonded LptD species 
  Since LptE is required for proper oxidation of LptD, we looked for intermediate LptD 
species in a strain reported to make low levels of LptE at certain points during its growth 
phase
105. OM fragments were isolated from both WT and LptE-limiting strains and were 
analyzed by SDS-PAGE followed by α-LptD and α-LptE immunoblot under both reducing (with 
β-mercaptoethanol, β-ME) and non-reducing (without β-ME) conditions (Figure 10). A novel 
LptD species was observed in the LptE-limiting strain (labeled intermediate 1). This species 
migrates slightly faster than reduced LptD, and it only exists in the absence of β-ME, suggesting 
that it contains at least one disulfide bond. 33 
 
 
Figure 10. Observation of a non-native disulfide-bonded LptD species under LptE-limiting 
conditions. α-LptD and α-LptE immunoblots of OM fragments obtained from WT and LptE-
limiting strains at early log phase, during which LptE levels are low in the LptE-limiting strain. 
Where indicated, β-ME was used to reduce disulfide bonds. 
  In order to assign the disulfide connectivity of the species observed in Figure 10, we 
performed immunoblot analysis of OM fragments obtained from WT cells bearing plasmids 
encoding LptD with various cysteine to serine mutations (Figure 11). LptDSSCC, which is only 
capable of forming a [3-4] disulfide, migrated indistinguishably from reduced LptD (LptDSSCC is 
LptD with its first and second Cys residues mutated to Ser). The species that each contain one 
interdomain disulfide, LptDSCSC and LptDCSCS, which are only capable of forming the [2-4] and 
[1-3] disulfides, respectively, both migrate more slowly than reduced LptD. Only LptDCCSS, 
which can only form the [1-2] disulfide, was shown to migrate faster than reduced LptD, 
establishing that the LptD species that is observed when LptE is limiting is [1-2]-LptD.  34 
 
 
Figure 11. Assignment of the novel LptD species as [1-2]-LptD. (A) α-His immonoblot of OM 
fragments obtained from WT cells expressing LptDSSCC-His, LptDSCSC-His, LptDCSCS-His, or 
LptDCCSS-His (LptDSSCC is LptD with the first and second Cys residues mutated to Ser, etc.). (B) 
α-LptD immunoblot of OM fragments obtained from WT cells and WT cells expressing a 
plasmid encoded copy of lptDCCSS. Where indicated, β-ME was used to reduce disulfide bonds. 
 
2.2.2. Accumulation of [1-2]-LptD in strains with defective LptD or LptE 
  In order to test how LptD biogenesis is affected in strains bearing defective copies of 
either lptD or lptE, we performed immunoblot analysis of OM fragments isolated from WT, 
lptDΔ330-352 (lptD4213)
107, lptEΔ100-101/P99R (lptE6)
127, and lptDΔ529-538
106 strains 
(Figure 12). In each of these mutants, significant amounts of intermediate 1 ([1-2]-LptD) 
accumulates in the OM, suggesting that all of these mutants cause defects in LptD biogenesis. 
Since [1-2]-LptD is not functional
125, this observation could explain the OM defects observed in 
each of these mutations.   
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Figure 12. Accumulation of [1-2]-LptD in strains defective in lptD or lptE. α-LptD and α-LptE 
immunoblots of OM fragments isolated from WT, lptDΔ330-352, lptEΔ100-101/P99R, and 
lptDΔ529-538 strains. The white arrowhead indicates the position of intermediate 1 ([1-2]-LptD). 
Where indicated, β-ME was used to reduce disulfide bonds. 
 
2.2.3. [1-2]-LptD is an intermediate in the LptD assembly pathway  
  In order to determine whether or not [1-2]-LptD is an intermediate along the in vivo LptD 
assembly pathway or a dead-end, off-pathway product, we pulse labeled 3x-FLAG tagged LptD 
with [
35S]-methionine and monitored its maturation following a cold methionine chase (Figure 
13). [1-2]-LptD was prominent at the beginning of the pulse-chase experiment, and after about 
thirty minutes, it is almost completely converted to [1-3][2-4]-LptD, establishing that it is an 
intermediate in LptD assembly. 36 
 
 
Figure 13. [1-2]-LptD is an on-pathway, in vivo intermediate in the LptD assembly pathway. 
WT cells expressing 3x-FLAG tagged LptD were pulse labeled with [
35S]-methionine and chased 
with cold methionine. Samples were taken at various time points, alkylated with N-
ethylmaleimide, immunoprecipitated with α-FLAG antibody, and analyzed by SDS-
PAGE/autoradiography. The white arrowhead indicates the position of intermediate 1. Where 
indicated, β-ME was used to reduce disulfide bonds. 
 
2.2.4. Folding of the LptD β-barrel occurs prior to disulfide rearrangement 
  Next, we performed a version of the pulse-chase experiment that preserved the folded 
state of the LptD β-barrel domain to determine when folding of the β-barrel occurs in relation to 
the formation and rearrangement of the [1-2] disulfide bond (Figure 14). The pulse-chase was 
conducted as in Figure 13, but the samples were processed in a non-denaturing fashion and were 
not heated, unless indicated in Figure 14, prior to analysis via seminative SDS-PAGE. The 
folding state of LptD can be assessed from this experiment by looking for heat-modifiability in 
the migration speed of the protein; the folded β-barrel is observed to migrate more rapidly than 37 
 
the denatured protein. The resulting gel shows that at initial time points, only unfolded, reduced 
LptD and unfolded [1-2]-LptD are present. As the chase progresses, both species become lost, 
and two new folded species appear. The faster-migrating of these bands corresponds to folded 
[1-2]-LptD, as judged by an unheated LptDCCSS control that can only form the [1-2] disulfide 
bond, and it chases away as the experiment progresses. The other faster-migrating species is the 
exclusive species present at later time points, leading to its assignment as folded [1-3][2-4]-
LptD. Heat modifiability of both of these faster-migrating bands is consistent with these 
assignments. Taken together, this experiment enables us to conclude that the disulfide 
rearrangement that forms mature LptD occurs after β-barrel assembly. Additionally, since folded 
[1-2]-LptD does not accumulate substantially during the chase, we conclude that folding, not 
disulfide rearrangement, is the slow step in LptD assembly.  
 
Figure 14. Disulfide rearrangement occurs after assembly of the LptD β-barrel domain. The 
pulse-chase experiment described in Figure 13 was performed, but the samples were processed in 
a non-denaturing manner and were not heated (unless indicated) prior to analysis by seminative 38 
 
SDS-PAGE/autoradiography. The white arrowhead marks the position of intermediate 1; the 
double white arrowhead marks the position of folded intermediate 1; the single and double 
asterisks mark the positions of the unfolded and folded [1-2]-LptDCCSS controls, respectively. 
Where indicated, β-ME was used to reduce disulfide bonds. 
 
2.2.5. The roles of DsbA and DsbC in LptD biogenesis 
  LptD is known to be a substrate of DsbA
126, and it is known that DsbA, but not DsbC, is 
important for proper oxidation of LptD
125. To determine the roles of DsbA and DsbC in LptD 
assembly, we analyzed isolated OM fragments from WT, ΔdsbA, and ΔdsbC strains grown in 
either rich (LB) or minimal medium (M63/Glc) (Figure 15A). At steady state, ΔdsbA cells grown 
in rich medium contain both mature [1-3][2-4]-LptD and an additional species, intermediate 2. 
Intermediate 2 migrates at the same speed as oxidized LptDSCSC, enabling us to assign it as being 
[2-4]-LptD. [2-4]-LptD, but not [1-3][2-4]-LptD, was observed when ΔdsbA cells were grown in 
minimal medium, suggesting that the mature LptD observed in ΔdsbA cells grown in rich 
medium is the result of a non-specific oxidant that is present in the medium. WT cells and ΔdsbC 
cells are able to exclusively produce [1-3][2-4]-LptD in either rich or minimal medium. Pulse-
chase experiments were also conducted in both the ΔdsbA and ΔdsbC backgrounds. In the ΔdsbA 
pulse-chase experiment, by 60 minutes, the pulse-labeled LptD‟s oxidation state resembled the 
makeup observed at steady state (Figure 15B and C). In this experiment, almost exclusively 
reduced LptD is present, with a trace of [2-4]-LptD (Figure 15). In the ΔdsbC pulse-chase 
experiment, the rate of LptD maturation is significantly slower than in the WT strain; by ~20 
min, LptD is almost completely oxidized in the WT strain, but in the ΔdsbC background, an hour 
is necessary before complete conversion is observed (Figure 16A). We propose that the role of 39 
 
DsbC is to reduce a [3-4] disulfide that also exists in the [1-2]-LptD species such that disulfide 
rearrangement can occur. To test this theory, the same pulse-chase experiment was conducted in 
the ΔdsbC background, but with LptDCCSC-3xFLAG instead of LptDCCCC-3xFLAG (Figure 16B). 
In this experiment, formation of a [3-4] disulfide is impossible, removing the need for DsbC to 
reduce it to enable disulfide rearrangement. Consistent with this hypothesis, we observed that 
rearrangement of [1-2]-LptD to [2-4]-LptD returned to a rate consistent with the WT strain, 
suggesting that DsbC‟s role in LptD assembly is to reduce a [3-4] disulfide prior to disulfide 
rearrangement.  
 
Figure 15. DsbA is required for formation of [1-2]-LptD. (A) α-LptD immunoblot analysis of 
OM fragments isolated from WT, ΔdsbA, and ΔdsbC strains grown in either rich (LB) or 
minimal medium (M63/Glc). Intermediate 2 is identified as being [2-4]-LptD using the indicated 
lptDCSCS and lptDSCSC controls. (B) α-FLAG immunoblot analysis of OM fragments isolated from 
WT or ΔdsbA cells containing pET23/42lptD-3xFLAG grown in minimal medium. (C) [
35S]-40 
 
Methionine pulse-chase, as in Figure 13, but conducted in a ΔdsbA background. Bands marked 
with an asterisk are LptD degradation products. Where indicated, β-ME was used to reduce 
disulfide bonds. 
 
Figure 16. DsbC acts as a reductant during LptD assembly. (A) [
35S]-Methionine pulse-chase 
experiment, as in Figure 13, conducted in a ΔdsbC background. (B) [
35S]-Methionine pulse-chase 
experiment, as in (A), but conducted using LptDCCSC-3xFLAG instead of LptDCCCC-3xFLAG. 
Where indicated, β-ME was used to reduce disulfide bonds. 
  To further explore the role of DsbA in LptD assembly, we used DsbAP151T, a point 
mutant in DsbA that forms slow-to-resolve mixed-disulfide adducts with its substrates
126. α-
FLAG immunoprecipitation followed by α-FLAG and α-DsbA immunoblot analysis was 
conducted on WT and dsbAP151T strains bearing pET23/42lptD-3xFLAG, and two DsbA-LptD 
adducts were observed (Figure 17A). The first species, adduct A, migrated slightly faster than [1-
3][2-4]-LptD, while the second species, adduct B, migrated more slowly than [1-3][2-4]-LptD. In 
order to establish the identity of these species, we performed the same analysis on dsbAP151T 
strains bearing a variety of pET23/42lptD-3xFLAG plasmids in which the encoded lptD genes 
contained all possible single and double cysteine to serine mutations (Figure 17C). The adducts 41 
 
were only detected when C31 was present, suggesting that both adducts are mixed disulfides 
between C31 and DsbA. Since adduct A is observed in double mutants in which no other 
disulfides are possible, we conclude that it must be [1-DsbA]-LptD. Adduct B is observed in 
LptDCCSC, which is known to exist as [2-4]-LptD
125, allowing us to conclude that adduct B is [2-
4][1-DsbA]-LptD. In this experiment, a third adduct is observed in LptDCCCS, which is known to 
exist as [2-3]-LptD
125, allowing us to conclude that this species is [2-3][1-DsbA]-LptD; this 
species is not observed in cells with WT lptD.  
 
Figure 17. DsbA-mediated oxidation forms the [1-2] and [1-3] disulfide bonds in LptD. (A) α-
FLAG and α-DsbA immunoblot analysis following α-FLAG immunoprecipitation from WT and 
dsbAP151T cells. Two DsbA-LptD adducts are detected, labeled A and B and indicated in red. (B) 
[
35S]-Methionine pulse-chase experiment using WT and dsbAP151T cells. New species 42 
 
corresponding to the DsbA-LptD adducts from (A) are observed. DsbA adduct A appears first 
and chases away, while DsbA adduct B appears later and chases away. (C) α-FLAG and α-DsbA 
immunoblot analysis following α-FLAG immunoprecipitation from dsbAP151T strains bearing 
plasmid encoded lptDCCCC-3xFLAG, lptDSCCC-3xFLAG, lptDCSCC-3xFLAG, lptDCCSC-3xFLAG, 
lptDCCCS-3xFLAG, lptDCSSC-3xFLAG, lptDCSCS-3xFLAG, and lptDCCSS-3xFLAG. [2-4][1-DsbA]-
LptD, open arrowhead; [1-DsbA]-LptD, closed arrowhead; [2-3][1-DsbA]-LptD, double 
asterisk; LptD degradation product, single asterisk.  
  We performed a pulse-chase experiment in the dsbAP151T/pET23/42lptD-3xFLAG 
background and were able to observe both of the [1-DsbA]-LptD and [2-4][1-DsbA]-LptD 
mixed-disulfide adducts (Figure 17B). [1-DsbA]-LptD is evident from the beginning of the 
experiment, and it chases away, presumably to form [1-2]-LptD by ~5-10 minutes. [2-4][1-
DsbA]-LptD begins to appear at around 2-5 minutes, as [1-2]-LptD begins to chase away, and it 
begins to disappear at around 10-20 minutes as [1-3][2-4]-LptD becomes predominant. 
 
2.2.6. Discussion 
  Taken together, the experimental observation of these six LptD intermediates allows us to 
establish a pathway for LptD oxidative assembly (Figure 18). Pre-LptD is translated in the 
cytoplasm with its signal peptide and then secreted across the IM by the Sec machine and 
processed by the signal peptidase. Following secretion, reduced LptD is oxidized by DsbA, via 
the [1-DsbA]-LptD mixed-disulfide intermediate, to form [1-2]-LptD. Evidence also suggests 
that a [3-4] disulfide might also exist in this species, but this has not been firmly established. 
Following this initial oxidation, unfolded [1-2]-LptD is processed by the Bam complex to give a 
folded β-barrel. The mechanism of this assembly, as well as LptE‟s role in it, remains poorly 43 
 
understood. Following folding, [1-2]-LptD undergoes a disulfide rearrangement to form [2-4]-
LptD. Evidence suggests that this step might be preceded by reduction of the possible [3-4] 
disulfide by DsbC. It is worth noting that this rearrangement is the step at which the OM LPS 
translocon becomes active, since a single interdomain disulfide linkage is sufficient for 
function
125. The folded, active [2-4]-LptD species is oxidized again by DsbA at the OM, via a [2-
4][1-DsbA]-LptD mixed-disulfide intermediate, to mature [1-3][2-4]-LptD. This species, which 
is the exclusive form of LptD present in steady-state WT cells, forms the OM portion of the 
complete Lpt complex.  
 
Figure 18. Schematic showing the oxidative assembly pathway of LptD, including the six 
experimentally observed LptD intermediates.  
  It is particularly noteworthy that the formation of the [2-4] disulfide represents the first 
active form of the complex because it is the more conserved of the two LptD disulfides and is 
present in more than 95% of >1000 surveyed non-identical LptD homologs (Figure 19). The [1-44 
 
3] disulfide is much less conserved, suggesting that the [2-4] disulfide plays a critical structural 
role in the function of the translocon.  
 
 
Figure 19. Cysteines 173 and 724/5 from E. coli LptD are highly conserved and are present in 
>95% of 1056 surveyed non-identical LptD homologs.  
  The disulfide rearrangement from an assembled [1-2]-LpD/LptE complex to an activated 
[2-4]-LptD/LptE complex provides a mechanism to guarantee that both LptD and LptE have 
been properly assembled together into a complex before they are activated. This model is 
supported by the observation that mutants defective in either LptD or LptE fail this check and 
remain in the [1-2] state (Figure 12). This is also consistent with the observation that [1-2]-LptD 
that accumulates in the LptE-limiting strain during growth phases when LptE is limited (as in 
Figure 10) is not seen when LptE levels are restored (Figure 20). From this, we conclude that 
activation of the LptD/E complex, via the disulfide rearrangement, is controlled by proper 
assembly of the LptD/E complex. It is also worth noting that the oxidation state of LptD is, in 
this way, controlled by LptE, which is not an oxidoreductase.  45 
 
 
Figure 20. Restoration of LptE restores proper LptD oxidation in an LptE-limiting strain. α-
LptD and α-LptE immunoblots of OM fragments isolated from an LptE-limiting strain that 
expresses low levels of LptE during early-log phase (“low LptE”) and higher levels of LptE 
during mid-log phase (“high LptE”). Intermediate 1, [1-2]-LptD, is indicated with an open 
arrowhead; reduced LptD is indicated with a solid arrowhead.  
It has also been previously observed that proper oxidation of LptD is necessary for its 
association with LptA
103. Therefore, the disulfide rearrangement provides a mechanism that 
ensures that only correctly assembled LptD/E species are incorporated into the trans-envelope 
complex. Perhaps this prevents the formation of non-functional LPS transporters or prevents 
inappropriate targeting of LPS.  
These findings also reveal that β-barrel assembly for LptD is the rate-limiting step in its 
maturation and is remarkably slow, taking about 20 minutes (about a third of a cell cycle under 
these conditions). In contrast, LamB assembly is several orders of magnitude faster
134. This delay 
in assembly might reflect a difficulty in assembling the complex plug-and-barrel structure that 
LptD/E is believed to adopt. This slow assembly might also present a target for inhibition of OM 
biogenesis, and could possibly be the mechanism by which the reported peptidomimetic 
antibiotic
130 functions. 46 
 
 
2.3. Materials and methods 
2.3.1. Bacterial strains and growth conditions 
For most experiments, the wild type strain used is MC4100 [F
- araD139 Δ(argFlac) 
U169 rpsL150 relA1 flbB5301 ptsF25 deoC1 ptsF25 thi]. The LptE-limiting strain used that 
makes varying levels of LptE according to growth phase is AM689 [MC4100 ara
+ lptE::kan 
λatt(PBAD-lptE)]
104. The lptDΔ330-352 (lptD4213), lptEΔ100-101/P99R (lptE6) and lptDΔ529-
538 mutant strains used are NR698
107, GC190 [MC4100 ara
+ ΔlptE2::kan pBAD18lptE6]
127 and 
MC4100 ΔlptD2::kan pET23/42lptDΔ529-538
106, respectively. The ΔdsbA and ΔdsbC strains 
used are NR1216 and NR1217
125, respectively. For experiments involving the dsbAP151T mutant, 
the wild type strain used is HK295, a MC1000 derivative [F
- Δara714 galU galK Δ(lac)X74 rpsL 
thi] and the dsbAP151T mutant used is HK348 [HK295 zin::Tn10 dsbAP151T]
126. Luria-Bertani (LB) 
broth and M63/glucose minimal broth and agar were prepared as described previously
135. 
Arabinose (0.2% w/v) was added for the growth of AM689
104 and GC190
127. Growth of strains 
was carried out at 37°C unless explicitly indicated. When appropriate, kanamycin (25 μg/ml) and 
carbenicillin (50 μg/ml) were added. Amino acids were added at 50 μg/ml when indicated. 
 
2.3.2. Plasmid construction 
To construct pET23/42lptD-FLAG3, a cassette containing the coding sequence of the 
FLAG3 tag was inserted into pET23/42lptD-His
104 to replace the original His8 tag. Briefly, the 
entire pET23/42lptD-His template was amplified by PCR (using primers 5‟- 
AGATCATGATATCGACTATAAAGACGATGATGACAAATAATTGATTAATACCTAGG
CTGC-3‟ and 5‟-47 
 
ATAGTCGATATCATGATCTTTGTAGTCGCCGTCGTGATCTTTATAATCGCGCGCCAA
GGC-3‟) and the resulting PCR product mixture was digested with DpnI for >1 h at 37°C. 
NovaBlue (Novagen) cells were transformed with 1 μl of digested PCR product and plated onto 
LB plates containing 50 μg/ml carbenicillin. For each construct, plasmids from six colonies were 
isolated and sequenced.  
To generate LptD Cys mutant constructs containing the FLAG3 tag, pET23/42lptDXXXX-
His constructs were first made via site-directed mutagenesis using relevant primers
125 and 
pET23/42lptD-His
104 as the initial template. Briefly, the entire template was amplified by PCR 
and the resulting PCR product mixture digested with DpnI for >1 h at 37°C. NovaBlue 
(Novagen) cells were transformed with 1 μl of digested PCR product and plated onto LB plates 
containing 50 μg/ml carbenicillin. For each construct, plasmids from six colonies were isolated 
and sequenced. The resulting pET23/42lptDXXXX-His constructs were used in the same protocol 
above to generate pET23/42lptDXXXX-FLAG3 constructs. 
 
2.3.3. Growth of AM689 for OM analysis 
10 ml cultures were grown overnight at 30°C in LB broth containing 0.2% arabinose. 
Cultures were pelleted and washed twice in equal an volume of LB broth. Fresh LB cultures (1.5 
l) containing 0.2% arabinose were inoculated with the washed cells to an initial OD600 of ~0.01 
and were grown at 30°C until OD600 reaches ~0.25 (~4 h) and ~0.5 (~5 h). The amount of cells 
equivalent to that in a 500 ml culture of OD600 ~0.5 was pelleted by centrifugation at 5000 x g 
for 20 min and subjected to OM analysis (see below). 
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2.3.4. Isolation of OM for analysis of LptD oxidation states 
  Strains MC4100, AM689, NR1216, NR1217, NR698, GC190 and MC4100 ΔlptD2::kan 
pET23/42lptDΔ529-538 were used for OM analysis. These strains contain a single copy of lptD 
expressed from the chromosome or plasmid. Strains MC4100 containing p(lptDCCCC) or 
p(lptDCCSS) (pET23/42lptD or pET23/42lptDCCSS, respectively
125), MC4100, NR1216, HK295 
and HK348 containing pET23/42lptD-FLAG3 were also used for OM analysis experiments. 
These strains contain two copies of lptD, one expressed from the chromosome and the other 
expressed from pET23/42. OM analysis is performed as previously described
125. Briefly, cells 
were pelleted by centrifugation at 5000 x g for 20 min and then resuspended in 5 ml Tris-B 
buffer (10 mM Tris-HCl, pH 8.0) containing 20% (w/w) sucrose, 1 mM phenylmethylsulfonyl 
fluoride (Sigma), 50 μg/ml DNase I (Sigma) and 50 mM iodoacetamide (IAM, Sigma). Cells 
were lysed by a single passage through a French Press (Thermo Electron) at 8,000 psi. ~8 ml of 
cell lysate was layered onto a two-step sucrose gradient (top – 4 ml Tris-B buffer containing 40% 
(w/w) sucrose, bottom – 1 ml Tris-B buffer containing 65% (w/w) sucrose) and centrifuged at 
39,000 rpm for 16 h in a Beckman SW41 rotor in an ultracentrifuge (Model XL-90, Beckman). 
OM fragments (~0.5 ml) were isolated from the 40%/65% interface by puncturing the side of the 
tube with a syringe. 1 ml of 20 mM Tris-HCl, pH 8.0 was added to the OM fragments to lower 
the sucrose concentration to below 20% (w/w). The OM fragments were then pelleted in a 
microcentrifuge at 18,000 x g for 30 min and then resuspended in 200-250 μl TBS (20 mM Tris-
HCl, 150 mM NaCl) containing 5 mM IAM. Protein concentration of these OM preparations 
were determined using Bio-Rad DC protein assay after precipitating in 10% trichloroacetic acid 
(TCA) and resolubilizing in TBS containing 2% SDS. The same amount of OM (based on 49 
 
protein content) for each strain was analyzed by non-reducing SDS-PAGE and immunoblotted 
using antibodies directed against LptD and LptE. 
 
2.3.5. Pulse-chase analysis 
  Strains MC4100, NR1216, HK295 and HK348 containing pET23/42lptD-FLAG3 were 
used in pulse-chase experiments. Pulse-chase experiments were essentially carried out according 
to published protocols
136. Briefly, a 5 ml culture was grown to OD600 ~0.5 in M63/glucose 
minimal media supplemented with eighteen amino acids (minus methionine and cysteine) at 
37°C. The culture was pulse-labeled with [
35S]-methionine (100 μCi/ml final concentration) 
(American Radiolabeled Chemicals) for 2 min and then chased with cold methionine (5 mM) at 
37°C. At the indicated time point during the chase, a 800 μl culture aliquot was transferred to a 
1.5 ml tube containing 80 μl of TCA (70% in water) and incubated on ice for 20 min. 
Precipitated proteins were pelleted at 18,000 x g for 10 min at 4°C, washed with 700 μl ice-cold 
acetone, and then solubilized in 80 μl 100 mM Tris-HCl, pH 8.0 containing 1% SDS and 20 mM 
N-ethylmaleimide (NEM, Sigma). The sample was sonicated for 30 s to aid solubilization. 
Following that, 800 μl of ice-cold IP buffer (50 mM Tris-HCl, pH 8.0 containing 150 mM NaCl, 
2% Triton X-100, 1 mM EDTA) was added and the sample was centrifuged at 18,000 x g for 10 
min at 4°C. 700 μl of the supernatant was transferred to another 1.5 ml tube containing 2.5 μl of 
anti-FLAG
® M2 magnetic beads (Sigma). The beads were washed and pre-equilibrated with 3 x 
1 ml IP buffer before use. The mixture was incubated on a rotary shaker for 1 h at 4°C, and the 
beads were washed with 3 x 800 μl of ice-cold high salt buffer (50 mM Tris-HCl, pH 8.0 
containing 1 M NaCl, 1% Triton X-100, 1 mM EDTA) and 1 x 800 μl ice-cold 10 mM Tris-HCl, 
pH 8.0 using a magnetic separation rack (New Englands Biolabs). 60 μl 2X SDS non-reducing 50 
 
sample buffer was then added to the beads and the mixture heated for 10 min at 100°C to elute 
the bound proteins. 15 μl of eluted sample was applied to SDS-PAGE directly. For reduction of 
disulfide bonds, 0.5 μl β-mercaptoethanol (β-ME, Sigma) was added to 20 μl eluted sample and 
heated for 5 min at 100°C before loading. 4-20% Tris-HCl polyacrylamide gels were used 
(running conditions: 150 V for 120 min). The gel was then dried and exposed to phosphor 
storage screens for autoradiography.  
 
2.3.6. Seminative pulse-chase analysis 
  Strain MC4100 containing pET23/42lptD-FLAG3 was used in seminative pulse-chase 
experiments. A 5 ml culture was grown to OD600 ~0.5 in M63/glucose minimal media 
supplemented with eighteen amino acids (minus methionine and cysteine) at 30°C. The culture 
was pulse-labeled with [
35S]-methionine (100 μCi/ml final concentration) (American 
Radiolabeled Chemicals) for 2 min and then chased with cold methionine (5 mM) at 37°C. At 
the indicated time point during the chase, an 800 μl culture aliquot was transferred to a 1.5 ml 
tube and pelleted at 18,000 x g for 1 min at 4°C. The cell pellet was resuspended in 100 μl lysis 
buffer (20 mM Tris-HCl, pH 8.0 containing 150 mM NaCl, 1% SDS, 0.5 mg/ml lysozyme, 1 
mM phenylmethylsulfonylfluoride (PMSF, Sigma), 1 mM EDTA and 40 mM NEM). After 
incubation for 2.5 min at room temperature, 1 ml of ice-cold IP-2 buffer (50 mM Tris-HCl, pH 
8.0 containing 150 mM NaCl, 2% n-octyl-β-glucoside (OG, Anatrace), 1 mM EDTA) was added 
and the sample was centrifuged at 18,000 x g for 30 min at 4°C. 950 μl of the supernatant was 
transferred to another 1.5 ml tube containing 2.5 μl of anti-FLAG
® M2 magnetic beads (Sigma). 
The beads were washed and pre-equilibrated with 3 x 1 ml IP-2 buffer before use. The mixture 
was incubated on a rotary shaker for 2 h at 4°C, and the beads were washed with 4 x 800 μl of 51 
 
ice-cold wash buffer (50 mM Tris-HCl, pH 8.0 containing 1 M NaCl, 2% OG, 1 mM EDTA) 
using a magnetic separation rack (New England Biolabs). 30 μl of ice-cold elution buffer (50 
mM Tris-HCl, pH 8.0 containing 150 mM NaCl, 2% OG, 1 mM EDTA, 250 μg/ml FLAG3 
peptide (Sigma)) was then added to the beads and the mixture incubated for 10 min at 4°C to 
elute the bound proteins. An equal volume of 2X SDS non-reducing sample buffer was added 
and the sample split into two – one applied to seminative SDS-PAGE directly and the other 
heated for 10 min at 100°C before loading. 10% Tris-HCl polyacrylamide gels were used 
(Running conditions: 150 V for 75 min, 4°C). The gel was then dried and exposed to phosphor 
storage screens for autoradiography. 
 
2.3.7. Bioinformatics 
  The list of non-identical LptD sequences was collected by BLAST. Using the E. coli 
LptD sequence as a start, an initial BLAST hit list was collected. The weak hits were then used 
as the new reference sequence to BLAST search for more LptD sequences. By doing this 
recursively for over 20 rounds, thousands of LptD sequences were collected. This initial list was 
then filtered to remove identical sequences and partial genes (usually containing deletions on one 
or the other end of the gene). The final list contains 1056 non-identical LptD sequences. 
 
2.3.8. Antibodies 
  Monoclonal α-His conjugated to horseradish peroxidase was purchased from Qiagen. 
Monoclonal α-FLAG conjugated to horseradish peroxidase was purchased from Sigma. α-
LptD
47, α-LptE
105, and α-DsbA
137 antisera were already described. 
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Chapter 3: Screening of N-LptD Crystallization Conditions 
 
Collaborators: Goran Malojcic, Shu Sin Chng, Daniel Kahne 
 
3.1 Introduction 
  There are a number of questions about the mechanism and biogenesis of LptD that could 
be addressed with the aid of an X-ray crystal structure, but as of yet, none have been reported. It 
is unlikely that a crystal structure of LptD alone is obtainable since LptE is required for LptD 
expression and likely performs an integral structural role in stabilizing LptD
105,106. 
Crystallization of LptD/E is an ambitious goal given the inherent difficulty associated with 
crystallizing membrane proteins, and it will be discussed further in Chapter 4. This chapter will 
discuss work towards the more straight-forward goal of obtaining a crystal structure of the 
soluble LptD N-terminal domain by itself (N-LptD; amino acids 25-203, 19771 Da, E. coli LptD 
numbering including signal sequence).  
  While having a crystal structure of the full-length LptD/E complex would be ideal, there 
are a number of questions that could be addressed by looking at only the structure of the N-
terminal domain. As discussed in Chapter 1, LptD is the target of a peptidomimetic antibiotic, 
and resistance to this drug is conferred by a tandem duplication of amino acids 210-215 
(LRDKGM) in the LptD N-terminal domain (numbering from P. aeruginosa LptD, including the 
signal sequence)
130. The mechanism of action for the drug and the mechanism by which this 
duplication affords resistance are unknown, but insight into these mechanisms could be provided 
by examining the structure of N-LptD. Additionally, this duplication lies just downstream of 53 
 
G207, N208, and V209, which are three of the most highly conserved residues in LptD homologs 
(see Figure 21). The proximal location of the resistance mutation to this nearly universally 
conserved stretch of amino acids suggests some, as of yet unknown, functional role for this 
portion of LptD. It is also worth mentioning that the peptidomimetic drug is only known to affect 
Pseudomonas spp., but not other Gram-negative organisms, including E. coli. The reason for this 
selectivity is not understood. Sequence alignments of LptD from P. aeruginosa and E. coli show 
that P. aeruginosa LptD contains a large (~90 amino acid) extension at the N-terminus that does 
not overlap with LptD from E. coli. This additional portion of P. aeruginosa LptD is predicted to 
be unstructured and contains two cysteine residues in addition to the four conserved cysteine 
residues that align with E. coli LptD. Comparison of N-LptD structures from these two species 
and from the drug resistant mutant might offer insights into both the drug‟s mechanism and N-
LptD‟s role in LPS trafficking.  54 
 
 
Figure 21. Multiple sequence alignment of the LptD N-terminal domain from four lptD 
homologs. The location of the amino acids duplicated in the P. aeruginosa drug resistance 
mutation is highlighted. Kpn, Klebsiella pneumonia; EC, E. coli; PA, P. aeruginosa; acinetob, A. 
baumannii. 
  The structure of N-LptD could also provide insight into the functional significance of the 
disulfide bond rearrangement that activates the LptD/E complex (see Chapter 2). N-LptD 
contains Cys31 and Cys173, which form the disulfide linkage in the inactive [1-2]-LptD species 
that exists as an intermediate during LptD biogenesis and accumulates in LptD/LptE defective 
mutants. It might be possible to crystallize N-LptD with and without cysteine residues in order to 
observe how the presence of the [1-2] disulfide affects the conformation of the N-terminal 
domain. This could provide a structural understanding of disulfide-mediated association with 
LptA and offer clues as to how the oxidation state of LptD affects its function.  55 
 
   As discussed in Chapter 1, N-LptD is predicted to be structurally homologous to both 
LptA and LptC and is known to interact with LptA during the formation of the trans-envelope 
bridge
103. The structures of both LptA and LptC have been reported and are shown in Figure 7 
and Figure 8, respectively
117,118. Both LptA and LptC assume a twisted β-jellyroll fold, and N-
LptD is predicted to do the same. The predicted secondary structure of N-LptD is consistent with 
this prediction and suggests that N-LptD consists of a large number of short β-strands (Figure 
22). The first 26 to 27 residues of N-LptD are predicted to be unstructured (numbering is of 
mature N-LptD, lacking the signal peptide), and Cys31 is located within this region. This is 
consistent with reports that DsbA acts non-specifically upon cysteine residues that are located in 
unstructured regions
138, and is also in line with the observation in Chapter 2 that DsbA acts twice 
upon this single residue to initially introduce the [1-2] intermediate disulfide bond and 
subsequently the [1-3] disulfide following disulfide rearrangement.  
  A protocol for the overexpression and purification of N-LptD has been reported
105, which 
provided a starting point for crystallization efforts. From there, we optimized the purification 
procedure and expression construct and screened for crystallization conditions in order to obtain 
diffracting crystals.  56 
 
 
Figure 22. N-LptD predicted secondary structure. The prediction was obtained using the E. coli  
N-LptD-His8 sequence and the PSIPRED v3.3 Protein Sequence Analysis Workbench (available 
at bioinf.cs.ucl.ac.uk/psipred/). The sequence used for this analysis was that of the mature N-57 
 
LptD protein lacking the signal peptide, and as such, the numbering of residues in this figure 
does not include amino acids 1-24 that make up the signal peptide. 
 
3.2. Results and Discussion 
3.2.1. Overexpression and purification of N-LptD-His8 and N-LptDSS-His8 
  N-lptD-His8 was overexpressed with its signal sequence, and the resulting protein was 
purified from the periplasm as reported
105. Additionally, a construct in which Cys31 and Cys173 
are mutated to serine, N-lptDSS-His8, was also overexpressed and the resulting protein was 
purified. The purified samples were analyzed by size exclusion chromatography (SEC) (Figure 
23 and Figure 24) and SDS-PAGE (Figure 25). Mostly pure protein was obtained in reasonable 
yield from each construct (roughly 0.8 to 1.25 mg per liter of culture), but several impurities 
were notable. Two high molecular weight contaminants were apparent, especially in the 
construct containing cysteines (referred to as N-LptDCC-His8 for clarity). These are observed as 
the two distinct bands that migrate at roughly 60 kDa and 75 kDa (Figure 25). Given the 
molecular weight of these species, they are likely the cause of the peak that elutes at roughly 13 
ml in Figure 23A. These species are suspected of being N-LptD oligomers, which is supported 
by the observation that peak fractions collected from SEC of N-LptDCC-His8 (collected fractions 
indicated by the red lines in Figure 23A) gave rise to the peak at 13 ml when analyzed again by 
SEC (Figure 23B), suggesting that there could be equilibration between monomeric and 
oligomeric N-LptD in solution. These contaminants were less evident in N-LptDSS-His8, but 
were still present (Figure 25). They are likely the cause of the shoulder observed during N-
LptDSS-His8 SEC (Figure 24). These proposed oligomers do not contain disulfide bonds, as they 
are observed in reducing conditions and in a cysteine-free construct.   58 
 
 
Figure 23. Size exclusion chromatograms of N-LptDCC-His8. (A) Size exclusion chromatogram 
following affinity purification of N-LptDCC-His8. (B) Chromatogram in which three fractions 
(A11-B1, indicated with red vertical lines) from (A) were collected and re-analyzed by size 
exclusion chromatography.  59 
 
 
Figure 24. Size exclusion chromatogram of N-LptDSS-His8. The chromatogram was obtained 
following affinity purification, as in Figure 23A. Pooled fractions B4-B6 were analyzed in 
Figure 25.  
 
Figure 25. SDS-PAGE analysis of purified N-LptDCC-His8 and N-LptDSS-His8. Lane 1 contains 
N-LptDCC-His8 following affinity purification but prior to size exclusion chromatography (SEC). 60 
 
Lane 2 is an analysis of the pooled eluate fractions obtained from SEC of the sample in lane 1. 
Lane 3 contains N-LptDss-His8 following SEC purification. Lane 4 is of the same sample as lane 
3, but after three weeks of storage at 4°C. All samples were reduced with β-ME prior to analysis.  
  The other contaminants that appear in the purified protein are bands that appear at a 
lower molecular weight than N-LptD. These bands are likely degradation products. This is 
supported by the observation that N-LptDSS-His8 that has been stored at 4°C for three weeks 
undergoes nearly complete decomposition into a ladder of lower molecular weight bands (Figure 
25, lane 3 vs. lane 4).  
   
3.2.2. Optimization of the expression construct 
  Protease protection experiments were conducted with N-LptDCC-His8 and N-LptDSS-His8 
in order to identify a minimal expression construct to use in crystallization screening (Figure 26). 
In these experiments, these two constructs were digested with various amounts of trypsin or 
subtilisin and analyzed by SDS-PAGE. Ideally, one would see a protease-stable, truncated 
fragment that might be useful as a construct for crystallization. In this case, no such stable 
fragment was observed, and complete loss of the protein occurs with increasing protease 
concentration.  
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Figure 26. Limited protease digestion of N-LptDCC-His8 and N-LptDSS-His8. Each lane was 
loaded with a sample from a reaction in which 1 mg/ml N-LptDXX-His8 was digested with some 
amount of either subtilisin or trypsin at 37°C for one hour. Lane 1 contained no protease. The 
samples loaded on lanes 2, 3, 4, 5, and 6 were digested with 4000, 800, 160, 32, and 6.4 ng/ml of 
subtilisin, respectively.  The samples loaded into lanes 7-11 were digested with the same 
concentrations as in lanes 2-6, but trypsin was used instead of subtilisin. All samples are reduced 
with β-ME. 
  The predicted secondary structure of N-LptD predicts that the first 26-27 amino acids are 
unstructured (Figure 22), and since unstructured regions are typically detrimental to protein 
crystallization, we decided to truncate N-lptD from its N-terminus to remove these residues. Five 
constructs were assembled by site-directed mutagenesis of N-lptDSS-His8 and tested for 
overexpression (Figure 27). Of these, only N-lptDC173S, ΔD26-G45-His8 overexpressed well and 62 
 
produced sufficient amounts of protein. These constructs were made in the cysteine-free 
construct as to prevent the introduction of unpaired cysteines that could lead to disulfide bonded 
oligomers and because the cysteine-free construct seemed to give a cleaner SEC chromatogram 
than the construct with cysteines (Figure 23 vs. Figure 24).  
 
Figure 27. N-terminal N-LptD truncation constructs. The indicated truncations were made in N-
lptDSS-His8. Expression level is indicated, and numbering for each deletion refers to E. coli LptD 
containing its signal peptide. 
  N-lptDC173S, ΔD26-G45-His8 was overexpressed and the resulting protein was purified. The 
yield was similar to that obtained from overexpression of N-lptDCC-His8/N-lptDSS-His8. When 
analyzed by SEC, the purified protein produced a chromatogram similar to the one obtained from 
N-LptDSS-His8 (Figure 28A). The purified sample, when analyzed by electrospray ionization-
mass spectroscopy (ESI-MS), shows a single peak of mass 18963.9388 Da (expected mass, 
18963.6 Da) (Figure 28B). This construct produces the cleanest and most stable N-LptD protein 
to date.  
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Figure 28. Analysis of purified N-LptDC173S, ΔD26-G45-His8. (A) Size exclusion chromatogram. 
(B) Deconvoluted ESI-MS spectrum.  
 
3.2.3. Screening of N-LptD crystallization conditions 
  Both N-LptDSS-His8 and N-LptDC173S, ΔD26-G45-His8 have been extensively screened for 
conditions that produce protein crystals. N-LptDSS-His8 has been screened at protein 
concentrations of 30, 20, and 10 mg/ml using Clear Strategy Screen I and Clear Strategy Screen 
II (Molecular Dimensions) at 4°C and 18°C. All of these combinations of temperature, protein 64 
 
concentration, and precipitant condition were also screened using N-LptDSS-His8 in which the 
lysine residues had been reductively methylated
139. No crystals were observed from any of these 
conditions. 
  N-LptDC173S, ΔD26-G45-His8 was screened both with and without lysine methylation, at 10 
mg/ml, at 4°C and 18°C, using JCSG+ (Qiagen), ProComplex (Qiagen), ComPAS (Qiagen), 
Clear Strategy Screen I (Molecular Dimensions), and Clear Strategy Screen II (Molecular 
Dimensions). Very small microcrystals were detected in a number of wells containing 
methylated protein (Figure 29). These crystals grew slowly over time, consistent with protein 
crystal growth patterns. The crystals were exceptionally small and not of sufficient size to test for 
diffraction. Each of the conditions described in Figure 29 was repeated on a larger scale (2 µl vs. 
300 nl droplet), but crystals failed to grow. Seeding of these crystals was not possible due to their 
size.  65 
 
 
Figure 29. Microcrystals of methylated N-LptDC173S, ΔD26-G45-His8. Images show growth of 
microcrystals over time in a representative crystallization condition. Inset: precipitant conditions 
that gave rise to these (bold) and similar crystals.  
 
3.2.4. Discussion and future work 
  The work described here, while not leading to diffracting crystals, does suggest that N-
LptD has the potential to be crystallized. It also provides a starting point for further refinement of 
the expression construct.  
  Going forward, it will be of the utmost importance to stabilize N-LptD such that it does 
not degrade appreciably over time. As is seen in Figure 25, degradation of each of these 
constructs represents a major problem that will most likely have to be better addressed before 
diffracting crystals are obtained. One way to stabilize the protein could be to find a better 
expression construct. Because of its interaction with LptA, it is also possible that co-purification 66 
 
of N-LptD with LptA could lead to a stabilized complex. Here we explored N-terminal 
truncations, but truncations from the C-terminus might also be beneficial. Installation of a 
protease-cleavable His-tag or an N-terminal His-tag might lead to a protein that is more stable 
and/or forms crystals more readily.   
  Using N-LptD from other species would also be a good idea moving forward. While we 
have found E. coli N-lptD to overexpress much better than P. aeruginosa N-lptD (expressed 
heterologously in E. coli; data not shown), expressing N-lptD from various organisms, 
particularly thermophilic organisms, could produce a more stable N-LptD protein that is better 
suited to crystallographic studies.  
  While the conditions identified here (Figure 29) do not produce useful crystals, they may 
provide a starting point from which better crystals can be grown. This could be done through the 
use of additive screening or by attempting to crystallize the protein using precipitant screens that 
are similar to the conditions that were identified for LptA/LptC crystallization. It is worth noting 
that the fibril forming crystal-form of LptA was only observed when LptA was crystallized in the 
presence of LPS
117. Similarly, it might be beneficial to screen for N-LptD crystallization in the 
presence of various purified LPS species.  
 
3.3. Materials and methods 
3.3.1. Strains and growth conditions 
  The strain BL21(λDE3) [F
- dcm ompT hsdS(r
-
Bm
-
B) gal(λDE3)] (Novagen) was used for 
protein overexpression. Luria-Bertani (LB) broth and agar were prepared as described 
previously
135. Antibiotics were used at 50 µg/ml unless otherwise indicated.  
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3.3.2. Overexpression and purification 
  Expression and purification of N-LptD proteins was modified from the previous reported 
protocol
105. Briefly, N-LptDCC-His8, N-LptDCC-His8, and N-LptDC173S, ΔD26-G45-His8 proteins 
were expressed and purified from BL21(λDE3) cells carrying the pET22/42N-lptDXX-His8 
plasmid. A 10 ml LB culture (supplemented with 50 µg/ml carbenicillin) was inoculated with the 
appropriate strain and grown at 37°C until OD600 ~0.6. 10 ml of this culture was used to inoculate 
each 1.5 l LB culture (supplemented with 100 µg/ml carbenicillin). A typical experiment 
involved growing several 1.5 l cultures. The 1.5 l cultures were grown at 24°C until OD600 ~0.6, 
at which point they were supplemented with 0.1 mM isopropyl-β-D-1-thiogalactopyranoside 
(IPTG) and grown for another 20 hours at 16°C. The cultures were centrifuged at 5,000 x g for 
10 minutes, and the cells were resuspended in 40 ml of cold TBS (20 mM Tris-HCl, pH 8.0, 150 
mM NaCl) (supplemented with 1 mM PMSF, 0.05 mg/ml DNase I, and 0.1 mg/ml lysozyme) per 
1.5 l culture that was centrifuged. The resuspended cells were lysed by a single passage through 
a French Press (Thermo) at 16,000 psi. The lysate was centrifuged for 10 min at 3,000 x g to 
remove unlysed cells, and the supernatant was centrifuged for 30 min at 100,000 x g in an 
ultracentrifuge (Model XL-90, Beckman; Type 45-Ti rotor). The supernatant was supplemented 
with 20 mM imidazole. 3 ml of Ni-NTA resin (Qiagen), as a 50% slurry, was added directly to 
the supernatant per 1.5 l culture being processed. The resulting mixture was rocked at 4°C for 2 
hr. The mixture was applied to a column and allowed to drain by gravity. The flow-through was 
reapplied to the column and drained again. The column was washed four times with five column 
volumes of TBS-A (20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 20 mM imidazole). The protein 
was eluted in two column volumes of TBS-B (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 200 mM 
imidazole). Protein was concentrated in an ultrafiltration device (Amicon Ultra, Millipore, 10 68 
 
kDa cut-off) and further purified by SEC using a pre-packed Superdex 200 column (GE 
Healthcare), using 20 mM HEPES pH 7.5, 300 mM NaCl as the eluent. Protein concentration 
was determined by NanoDrop spectrophotometer (Thermo, A280 measurement). Protein 
concentration was calculated using extinction coefficients as determined by ExPASy ProtParam 
tool (available at web.expasy.org/protparam/). ESI-MS was conducted using a micrOTOF-QII 
mass spectrometer (Bruker) and was processed and deconvoluted using Bruker Compass 
DataAnalysis 4.0. SDS-PAGE was performed using 4-20% Tris-HCl polyacrylamide gels as 
previously published
140. Gels were run at 150 V for 1 hr.  
 
3.3.3. Limited protease digestion 
  Purified N-LptDCC-His8 or N-LptDSS-His8 was diluted to 1 mg/ml in TBS. The solution 
was subdivided into 11 separate 20-µl reactions. Subtilisin (Sigma) was added to five these 
reactions at concentrations of 4000, 800, 160, 32, and 6.4 ng/ml. Trypsin (Sigma) was added to 
five of the remaining reactions at 4000, 800, 160, 32, and 6.4 ng/ml. The remaining reaction 
contained no protease. Each reaction was incubated at 37°C for 1 hour and then quenched with 2 
µl of 100 mM PMSF. Samples were analyzed by SDS-PAGE, as described above.  
 
3.3.4. Lysine methylation 
  Methylation of exposed lysine residues was carried out as reported
139. In brief, the protein 
was concentrated to 1 mg/ml in 20 mM HEPES, 300 mM NaCl. 20 µl of freshly prepared 1 M 
borane-dimethylamine complex (Sigma) and 40 µl 1 M formaldehyde (Sigma) were added per 
ml of protein solution. The solution was gently rocked and incubated at 4°C for 2 hr. Another 20 
µl 1 M borane-dimethylamine complex and 40 µl 1 M formaldehyde were added per ml of 69 
 
solution, and the solution was gently rocked and incubated at 4°C for another 2 hr. Following 
this incubation, a final 10 µl of 1 M borane-dimethylamine complex was added per ml of 
solution, and the reaction was gently rocked and incubated at 4°C overnight. The next day, the 
reaction was quenched by the addition of 20 mM Tris-HCl, pH 8.5 (from 1 M stock). Following 
methylation, the sample was concentrated using an ultrafiltration device (Amicon Ultra, 
Millipore, 10 kDa cut-off), subsequently diluted with 20 mM HEPES pH 7.5, 300 mM NaCl, and 
concentrated again for at least three cycles until remaining formaldehyde/borane-dimethylamine 
complex is confidently removed. The resulting protein was concentrated for use in crystallization 
experiments.  
 
3.3.4. Plasmid construction 
  Construction of pET22/42N-lptDCC-His8 was previously reported
105. To create the 
cysteine-free variant, this plasmid was mutagenized twice with QuickChange site-directed 
mutagenesis (Stratagene) using primers shown in Table 1. Primers C31S F and C31S R were 
used to insert the C31S mutation, and primers C173S F and C173S R were used to insert the 
C173S mutation, as previously reported
125. Briefly, the template plasmid was amplified by PCR 
using the indicated primers. The resulting PCR product was digested with DpnI (New England 
Biolabs) for 1 hr at 37°C. 1 µl of the digested PCR product was used to transform NovaBlue 
(Novagen) cells. The transformed cells were plated onto LB-agar plates that were supplemented 
with carbenicillin. Mutagenesis was confirmed by sequencing.  
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Table 1. Primers used in this chapter. 
 
N-terminal N-LptD truncation mutants were made as described above using site-directed 
mutagenesis with p22/42N-lptDSS-His8 as a template. Primers ΔA25-N48 F and ΔA25-N48 R 
were used to remove amino acids A25 through N48, and so on (Table 1).  
 
3.3.5. Crystallization 
  For screening of crystallization conditions, purified N-LptDSS-His8 or N-LptDC173S, ΔD26-
G45-His8 was prepared as above and concentrated to the indicated concentration (e.g. 10, 20, or 30 
mg/ml). The protein sample was dispensed using an Art Robbins Instruments Phoenix drop-
setting robot into 96-well sitting drop crystallization plates (Intelli-Plate 96-3 LVR, Art Robbins 
Instruments). Crystallization droplets contained 150 nl protein and 150 nl precipitant solution, 71 
 
and the reservoir solution contained 70 µl of the precipitant solution. The following precipitant 
screens were used: Clear Strategy I (Molecular Dimensions), Clear Strategy II (Molecular 
Dimensions), JCSG+ (Qiagen), ComPAS (Qiagen), and ProComplex (Qiagen). Plates were 
stored at either 4°C or 18°C and imaged in a crystallization hotel (Formulatrix) 
  Larger scale crystallization was set by hand in 24-well sitting drop Cryschem 
crystallization plates (Hampton). The precipitant solution was made by hand from individual 
components. The reservoir of each well was filled with 750 µl of the precipitant solution. 
Various droplet volumes were used; 1 µl to 1 µl,  2 µl to 2 µl, 1 µl to 2 µl, 2 µl to 1 µl, 1 µl to 3 
µl, and 3 µl to 1 µl of protein to precipitant were used.  
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Chapter 4: Crystallization of the LptD/E Complex 
 
Part of this chapter is adapted from: Chimalakonda, G., Ruiz, N., Chng, S. S., Garner, R. A., 
Kahne, D., and Silhavy T. J. Lipoprotein LptE is required for the assembly of LptD by the β-
barrel assembly machine in the outer membrane of Escherichia coli. Proceedings of the National 
Academy of Sciences of the United States of America, 108, 2492-2497, (2011). 
 
Collaborators: Goran Malojcic, Daniel Kahne 
 
4.1 Introduction 
  An X-ray crystal structure of the LptD/E complex (E. coli LptD, amino acids 25-784, 
87.1 kDa; E. coli LptE, amino acids 19-193, 19.4 kDa) will be necessary to ultimately confirm 
the plug-and-barrel model, answer a number of questions regarding the mechanism of LPS 
transport, and understand the structural significance of the translocon-activating disulfide bond 
rearrangement. Determination of this structure represents a challenging problem given that it is a 
complex of two membrane proteins. Several crystal and NMR structures of LptE alone are 
available (crystal structure from Shewanella oneidensis, PDB accession code 2R76; NMR 
structure from Nitrosomonas europaea, PDB accession code 2JXP; structure from N. 
meningitidis, PDB accession code 3BF2; crystal structure from E. coli, PDB accession code 
4NHR), but only the structure from E. coli has been published
141. These structures are all very 
similar, and they show that LptE contains a three-stranded β-sheet that is packed against two α-
helices and a shorter β-strand (Figure 30A).  73 
 
 
Figure 30. X-ray crystal structure of Shewanella oneidensis LptE (PDB accession number 
2R76). (A) Monomer. (B) Dimer, as observed in the crystal structure. 
While the plug-and-barrel model for the LptD/E structure is heavily supported by 
experimental evidence
106, it has not been completely confirmed, and its exact nature is unknown. 
While the basic model is that LptE is simply situated inside of the lumen of the LptD β-barrel, it 
also seems possible that LptD/E could form a β-barrel in which the β-strands of LptE contribute 
to the overall β-barrel architecture. This possibility is suggested because LptE and LptD form a 
nearly inseparable complex
105, because LptE is required for LptD β-barrel assembly
105,127 and 
oxidation
125, and because LptE contains a β-sheet that interacts with another molecule of LptE in 
the crystal structure to form a larger β-sheet (as in PDB assession code 2R76; see Figure 30B). 
Additionally, a crystal structure could be used to address the structural basis for phenotypes 
caused by the lptD4213, lptDΔ529-538 and lptE6 mutant alleles that were described in Chapters 1 
and 2. In particular, the phenotype caused by lptDΔ529-538 is proposed to be caused by a loss of a 
contact between LptE and a putative extracellular loop of LptD
106, and the lptE6 phenotype is 74 
 
proposed to be caused by a loss of affinity between LptD and LptE
127. A crystal structure of 
LptD/E will likely clarify the cause of each of these phenotypes while also addressing the 
mechanisms behind their suppressors.  
An LptD/E crystal structure would be useful in determining the path and mechanism by 
which LPS moves through LptD/E and into the membrane. While it has been proposed that four 
conserved proline residues in LptD (P214, P246, P483, and P510) create a lateral opening that 
enables LPS access to the OM
106, this has not been confirmed. In addition, questions remain 
regarding whether LptE plays a functional or purely structural role in LPS transport. In N. 
meningitidis, LptE is reported to be unnecessary for LPS transport
142. In contrast, LptE from E. 
coli has been reported to bind LPS in vitro
105. This has been supported by more recent work 
where LptE was shown to affect the aggregation state of LPS in vitro and where point mutations 
were identified in LptE that led to OM permeability in vivo and disrupted the ability of LptE to 
affect LPS aggregation in vitro
141. While recent evidence suggests that LptE plays a functional 
role in LPS transport, its specific function is unknown, but could potentially be clarified with the 
aid of a crystal structure showing how LptD interacts with LptE. Such a structure might also 
reveal different conformations of the complex, which could provide clues as to how LptE is 
involved in the handling of LPS.  
The structural significance of the disulfide bond rearrangement discussed in Chapter 2 
remains unknown. First of all, it is unclear why the inter-domain disulfide bonds are essential. It 
could be that they are necessary to orient the two domains relative to one another to enable 
passage of LPS from one domain to the next, or it could be that the presence of these disulfides 
triggers a conformational change, or even an ordering, of the N-terminal domain such that it 
becomes capable of forming an interaction with LptA that is suitable for LPS transport. It is also 75 
 
not clear why the disulfide bond rearrangement is used in vivo to activate the LPS exporter. It 
could be that this is to prevent mistargeting of LPS by disallowing misassembled LptD/E 
complexes from being incorporated into Lpt complexes, or it could be that the rearrangement 
step is simply the only possible way to form the necessary long-range disulfide bonds within the 
folded core of the LptD/E plug-and-barrel structure, which, given its complexity, might 
otherwise be inaccessible to DsbA. A crystal structure showing the locations of these disulfide 
bonds and their effects on the conformation of the LptD/E complex could help address these 
questions.  
  A protocol for the overexpression and purification of the LptD/E complex has been 
published
105, providing a starting point for efforts to obtain its crystal structure. In addition, it has 
been shown that the C-terminal β-barrel domain of LptD overexpresses and assembles with LptE 
in a stable complex that can be purified
105. This may represent a construct that is better suited for 
crystallography given the troubles with N-LptD stability that were described in Chapter 3. While 
this construct would make it difficult to address questions about the disulfide bonds, it would still 
be useful for addressing questions regarding the mechanism of LPS transport and LptE‟s role in 
it.  
 
4.2. Results and Discussion 
4.2.1. Purified LptD/E contains identifiable impurities 
  LptD/LptE-His6 were overexpressed from BL21(λDE3) cells harboring pET23/42lptD 
and pCDFlptE-His6 and purified via Ni-NTA affinity chromatography and SEC as previously 
reported
105. The resulting protein preparation was analyzed by SDS-PAGE and found to contain 
significant amounts of several specific contaminants that co-eluted with LptD/E following SEC 76 
 
(Figure 31A). Several of these contaminants were identified by MS analysis as being 
components of cytochrome o oxidase. The previously reported strategy for dealing with these 
impurities was to extract the isolated total membranes with N-lauroylsarcosine, a detergent that 
specifically solubilizes the IM but not the OM, prior to extraction with anzergent 3-14, which 
solubilizes both IM and OM
105. We found this additional extraction step to be time consuming, 
dirty, and detrimental to protein yield, which was already quite low. Since cytochrome o oxidase 
is non-essential, we deleted the genes, cyoA-E, that encode the cytochrome o oxidase proteins in 
our expression strain. Neither cell growth nor protein yield was impaired by this deletion. 
LptD/E purified from the resulting strain lacked these contaminating proteins (Figure 31B). All 
expression strains used hereafter in this chapter contain the cyoA-E::kan allele.   
  In addition to contamination by cytochrome o oxidase, N-terminal degradation of LptD 
was observed in most batches of purified LptD/E, as determined by Edman degradation/MS 
sequencing. This issue was found to become more notable in batches of protein as they aged, as 
observed with purified N-LptD in Chapter 3 (Figure 25). Because of this, a construct that lacks 
the N-terminal domain will likely improve the chances obtaining a diffracting crystal.  77 
 
 
Figure 31. Contaminants present in purified LptD/E. (A) SDS-PAGE analysis of purified 
LptD/LptE-His6 following SEC. Cyo proteins were identified by MS sequencing. (B) SDS-
PAGE analysis of purified LptD/LptE-His6, following SEC, from a ΔcyoA-E::kan strain. 
 
4.2.2. Purification of LptD/LptE6-His6 and LptD4213/LptE-His6 
  LptD/LptE6-His6 was overexpressed and purified in order to gauge its usefulness as a 
possible crystallography construct. Protein was obtained for this mutant, and the LptD/LptE6-
His6 and wild-type LptD/LptE-His6 complexes were found to be similarly stable (Figure 32). 
Both complexes migrate similarly and in a heat-modifiable manner during seminative SDS-
PAGE (Figure 32A). Both complexes also display similar susceptibility to trypsin digestion 
(Figure 32B). Based on these data, LptE6 containing complexes might be suitable for 
crystallization experiments.  78 
 
 
Figure 32. LptD/LptE-His6 and LptD/LptE6-His6 are similarly stable. (A) Seminative SDS-
PAGE analysis of purified LptD/LptE-His6 and LptD/LptE6-His6. All samples were reduced 
with β-ME; samples were heated as indicated. (B) Limited trypsin digestion of purified 
LptD/LptE-His6 and LptD/LptE6-His6. Truncated proteins are indicated with an asterisk (*). 79 
 
  LptD4213/LptE-His6 was also overexpressed and purified. This construct yielded lower 
amounts of protein, and heavy aggregation of the purified protein was observed. When analyzed 
by seminative SDS-PAGE, the complex migrates as expected when not heated (Figure 33A). 
When heated, however, much less LptD and LptE are observed than expected, and heavy 
aggregation was observed in the form of protein that fails to enter the gel. LptD4213/LptE-His6 
complex that is treated with trypsin displays the degradation pattern that is largely expected 
(Figure 33B, as compared to Figure 32B), but heavy aggregation was observed in each reaction, 
including the 0 mg/ml trypsin control. Additional bands that appear to correspond to previously 
unobserved LptD degradation are also seen for this mutant complex. While this complex is 
similarly stable to protease digestion, it seems to readily aggregate, and as such, it is likely a poor 
candidate for crystallography.  80 
 
 
Figure 33. Stability of purified LptD4213/LptE-His6. (A) Seminative SDS-PAGE analysis of 
purified LptD4213/LptE-His6. All samples were reduced with β-ME; samples were heated as 
indicated. (B) Limited trypsin digestion of purified LptD4213/LptE6-His6. Trypsin 
concentrations and digestion conditions are identical to Figure 32B. Truncated proteins are 
indicated with an asterisk (*).  
 
4.2.3. Purification of C-LptD/LptE-His6 and C-LptD-His8/LptE 
  C-LptD/LptE-His6 was overexpressed and purified. Because lptD is overexpressed at low 
levels, and since wild-type lptD is still present in the cell since C-lptD is not sufficient for 
viability, preparations of C-LptD/LptE-His6 are often contaminated with significant quantities of 
LptD/LptE-His6. This is due to the placement of the His-tag used for affinity purification on 
LptE, which can form a complex with either C-LptD or wild-type LptD. While of different sizes, 81 
 
these complexes are not completely resolvable by SEC (Figure 34A); as a result, preparations of 
C-LptD/LptE-His6 are more heterogeneous than is preferred for crystallography. Movement of 
the affinity tag to C-LptD from LptE enables direct pull-down of C-LptD/LptE during affinity 
purification, removing wild-type LptD contamination (Figure 34B). In general, we believe this 
construct represents a better candidate for crystallization.  
 
Figure 34. SEC chromatograms of C-LptD/LptE-His6 and C-LptD-His8/LptE preparations. (A) 
SEC chromatogram of C-LptD/LptE-His6 following affinity purification. Unresolved 
LptD/LptE-His6 peak is indicated. Retention volumes for the wild-type and C-LptD complexes 
are consistent with published values
105. (B) SEC chromatogram of C-LptD-His8/LptE.  
 
4.2.4. Optimization of the purification protocol to increase protein yield 
  The extremely low yield of LptD/LptE is the principal limiting factor in obtaining 
crystals. As discussed earlier, the removal of the initial N-lauroylsarcosine extraction was critical 82 
 
for increasing protein yield. In addition, we screened different solubilization conditions and 
found that using LDAO (n-dodecyl-N,N-dimethylamine-N-oxide or n-lauryldimethylamine-N-
oxide) to solubilize isolated membranes at room temperature provided the best yield of protein 
(Figure 35). These changes together improved protein yield by roughly 50-100%, depending on 
batch-to-batch variation. Despite these improvements, protein yield is still extremely low and is 
limiting to this work, with typical yields of ~0.1 to 0.15 mg of protein per liter of culture. These 
expression levels are just high enough that the growth of large volumes of culture can be 
performed to make crystallography feasible.  
 
Figure 35. Screening of C-LptD/LptE solubilization conditions. DDM (n-dodecyl-β-D-
maltopyranoside), ZW3-14 (anzergent 3-14), and LDAO (n-lauryldimethylamine-N-oxide) were 
used to solubilize membranes isolated from cells overexpressing C-lptD/lptE-His6. Extraction 
was performed at either 4°C or 24°C.   
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4.2.5. Screening of C-LptD/LptE-His6 crystallization conditions 
  Despite contamination by wild-type LptD, purified C-LptD/LptE-His6, solubilized with 
1% OG (n-octyl-β-D-glucoside), was exhaustively screened for conditions that produce crystals. 
Most available precipitant screens were utilized, including MemGold, ProComplex, ComPAS, 
PEGs I & II, Clear Strategy Screen I & II, JCSG+, Crystal Screen I & II, MemPlus, MemFac, 
and MemSys (all from either Qiagen or Molecular Dimensions). All screening was done with 
OG solubilized protein. Screens were also conducted at both 4°C and 18°C. Images of the most 
promising crystals and the conditions from which they were obtained are shown (Figure 36A, C, 
and D). These crystals were observed in 96-well plates, and when these crystals were grown 
again on a larger scale, only the crystals from Figure 36A grew. These crystals were analyzed for 
X-ray diffraction and diffracted to 10-13 Å (Figure 36B). While diffraction of this resolution is 
not sufficient to solve the structure, it does provide promise of better diffraction under different 
conditions or with different constructs.  84 
 
 
Figure 36. C-LptD/LptE-His6 crystals and X-ray diffraction. (A) C-LptD/LptE-His6 crystals 
obtained from OG solubilized protein at a 3:1 ratio of protein to precipitant, where 0.1 M MgCl2, 
0.1 M NaCl, 0.1 M Tris-HCl pH 8.5, 33% v/v PEG 400 is the precipitant. (B) Example of X-ray 
diffraction pattern resulting from the crystals from (A). (C) C-LptD/LptE-His6 crystals obtained 
from OG solubilized protein at a 3:1 ratio of protein to precipitant, where 0.1 M NaCl, 0.1 M 
sodium phosphate pH 7.0, 33% v/v PEG 300 is the precipitant. (D) C-LptD/LptE-His6 crystals 
obtained from OG solubilized protein at a 1:1 ratio of protein to precipitant, where 0.01 M 
calcium acetate, 0.1 M Tris-HCl pH 8.5, 3% w/v PEG-3000 is the precipitant. 
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4.2.6. Screening of C-LptD-His8/LptE crystallization conditions 
  Purified C-LptD-His8/LptE was also screened extensively for conditions that produce 
crystals. Unlike the previously described screening, emphasis was placed on screening using a 
variety of detergents, not just OG. Glucoside detergents have not widely been reported in OM β-
barrel protein structures, so we decided to focus on detergent classes that have historically been 
more successful for proteins of this class. In particular, polyoxyethylene detergents, such as C8E4 
(n-octyltetraoxyethylene) and C8E5 (n-octylpentaoxyethylene), have been used in crystallization 
for approximately half of the reported monomeric and dimeric OM β-barrel protein structures. 
Many of the remaining structures utilized LDAO and related detergents. Virtually none have 
reported success with maltosides. As such, we systematically screened for crystallization 
conditions using the same five precipitant screens (MemGold I & II, Clear Strategy I & II, 
MemPlus; all from Molecular Dimensions) at both 4°C and 19°C, with and without lysine 
methylation, in combination with 1% OG,  0.1% LDAO, 0.8% C8E4, 0.75% C8E5, 0.14% Fos-12 
(n-dodecylphosphocholine), 0.1% LDAO + 0.8% C8E4, and 0.05% LDAO + 1.67% heptane-
1,2,3-triol solubilized C-LptD-His8/LptE. Crystals were obtained from many conditions, 
especially from LDAO, OG, and C8E4 solubilized protein preparations. Representative crystals 
are shown (Figure 37). No significant diffraction was obtained from any of these crystals.  86 
 
 
Figure 37. C-LptD-His8/LptE crystals obtained from detergent screening. Representative 
crystals are shown for protein solubilized with (A-B) C8E4, (C) OG, and (D) Fos-12. Crystals in 
(B) were obtained with methylated protein, while the others were not. All crystals shown were 
obtained at 19°C. The precipitant condition is indicated.  
  Given the lack of diffraction obtained from traditional in surfacto crystallization, we 
screened for crystallization conditions using bicelle solubilized protein. This was also partly 87 
 
motivated by several recently reported β-barrel membrane protein structures that were obtained 
through the use of bicelles, including BamA
58. While the detergents mentioned previously form 
micelles in solution, bicelles form membrane-like discs that are intended to better emulate the 
membrane environment in which the protein natively resides. They also better allow lateral 
contacts between proteins in the membrane, making them useful for crystallizing proteins 
without large hydrophilic domains that could otherwise mediate crystal contacts. Bicelles also 
have the advantage of being easy to use and generally compatible with our existing screening 
systems. Unfortunately, bicelles tend to generate false-positive lipid crystals and the resulting 
protein crystals are often two-dimensional. False-positive crystals can typically be detected by 
screening crystals for UV fluorescence, which is a property of protein, but not lipid, crystals. In 
general, bicelles are composed of a mixture of two lipids, one that forms a membrane bilayer and 
one that forms a micelle. The two types of lipids are arranged in such a way that the bilayer-
forming lipid assembles into membrane-like bilayer whose edges are capped by the micelle 
forming lipid. The typical lipids that are used are DMPC (dimyristoylphosphatidyl choline) and 
CHAPSO (3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate), which 
form bilayers and micelles, respectively
143.  
  Purified C-LptD-His8/LptE that was solubilized in either C8E4 or OG was mixed 4:1 with 
a range of concentrations of bicelles (40%, 35%, 30%, or 25% 2.8:1 DMPC:CHAPSO) and 
screened using the five precipitant screens discussed above. All screening was done at 19°C, as 
bicelles are incompatible with screening at 4°C. No crystals were obtained with OG solubilized 
samples, but many conditions produced crystals with the C8E4 solubilized samples. The most 
reliably reproducible condition produced the crystals shown below (Figure 38).  
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Figure 38. Crystals of C-LptD-His8/LptE obtained using bicelles. The precipitant used was 400 
mM KSCN, 100 mM sodium acetate, pH 4.5, 11% w/v PEG 4K. (A) Bright field; (B) UV.  
The crystals shown in Figure 38 did not diffract particularly well (>20 Å resolution), so 
we used this condition as a starting point from which to screen for additives. Many additive 
conditions were found to produce crystals, and a number of varied crystal morphologies were 
observed. The resulting crystals were repeated on a larger scale and screened for diffraction. Of 
the identified additives, 200 mM NaSCN had the greatest effect on diffraction. Crystals grew 
reliably from this condition and are shown below (Figure 39). While the crystals shown here 
largely form needles, the best diffracting crystals occurred as two-dimensional plates. No well-
formed three-dimensional crystals were observed for this condition. Diffraction quality seems to 
track well with crystal size, with only the larger crystals showing reasonable diffraction. Seeding 
of these crystals to produce larger crystals was attempted, but was not successful. 89 
 
 
Figure 39. C-LptD-His8/LptE crystals obtained from additive screening. The precipitant 
condition is as described in Figure 38, but with an added 200 mM NaSCN. (A) Bright field; (B) 
UV.  
  A complete 360° data set was obtained from these crystals. Exemplary diffractograms 
from the dataset are shown below (Figure 40). The diffraction limit for the data set was 3.85 Å. 
These data processed into the space group P22121 (#18), with unit cell parameters of a=108.42 Å, 
b=128.86 Å, c=136.73 Å, and α=β=γ=90ﾰ (Table 2). These data are anisotropic, possibly a result 
of the two-dimensional crystal morphology. The crystal also suffered from radiation damage. 
Another partial data set was collected from a different crystal in which the diffraction limit was 
3.2 Å, but radiation damage prevented the collection of a complete data set. Assuming a 
molecular weight of 80 kDa, there appear to be two molecules in the asymmetric unit, with a VM 
of 2.98 Å
3/Da, corresponding to a solvent percentage of 58.82%. The presence of a bicelle or 
detergent micelle may contribute significantly such that only one molecule is present in the 
asymmetric unit.  90 
 
 
Figure 40. Exemplary diffractograms from a 3.85Å data set obtained from C-LptD-His8/LptE 
crystals. Images are shown at two angles, φ and φ+150ﾰ.  91 
 
Table 2. Crystallographic parameters and statistics associated with data shown in Figure 40. 
 
4.2.7. Phasing of C-LptD-His8/LptE diffraction data 
  Phasing of the 3.85Å C-LptD-His8/LptE data set was attempted using molecular 
replacement. A number of structures were used as search models, including E. coli LptE and a 
number of large Gram-negative β-barrel proteins, including FhuA (1QJQ), FimD (3OHN), AlgE 
(4AFK), and PapC (3FIP). Of these, only LptE and FimD returned solutions. The solution 
provided by LptE showed only LptE in isolation, while the FimD solution shows a large β-barrel 
with an area of unassigned electron density at its center, possibly suggesting the presence of 
LptE. Both of the resulting electron density maps are noisy and difficult to interpret; refinement 92 
 
does not improve the electron density map or the model, and the resulting R factors are 
significantly worse than what can be tolerated at this resolution.  
  Since a suitable molecular replacement model was not available, we pursued 
experimental methods of phasing. First, SeMet (L-selenomethionine) derivatized C-LptD-
His8/LptE was overexpressed, purified in C8E4, and crystallized as above. Crystals grew under 
these conditions, but were generally smaller. The smaller size of these crystals is likely a result 
of the lower protein concentrations used when setting up crystallization experiments with SeMet 
labeled protein. The lower concentration was largely necessitated by the lower yields obtained 
for SeMet labeled protein (roughly 50% that of native protein). Diffraction obtained from these 
crystals has so far been too weak to be useful, with resolutions of 10-20 Å.  
  Next, we screened for heavy atom compounds that can derivatize purified C-LptD-
His8/LptE by using a gel shift assay (Figure 41). In this experiment, purified C-LptD-His8/LptE 
was incubated with various heavy atom containing molecules and then analyzed by native PAGE 
to look for changes in migration speed that are due to the additional positive charge from the 
heavy atom. While difficult to interpret due to poor resolution of the bands, this experiment 
seems to indicate that C-LptD-His8/LptE is modified by two mercury containing compounds, 
HgCl2 and K2HgI4. Labeling with mercury is consistent with the presence of two cysteine 
residues in C-LptD, which were reduced with dithiothreitol (DTT) prior to heavy metal 
incubation in order to allow for possible mercury derivatization. Protein incubated with these two 
compounds migrated slightly slower than unlabeled protein in the gel shift assay, signifying the 
presence of additional positive charge on these proteins. Unfortunately, there is no control in this 
experiment to verify that this band is LptD/LptE (since migration speed is not proportional to 
protein size in this type of gel), and upon staining, it was evident that there was a significant 93 
 
amount of protein that aggregated and never entered the gel. Therefore, it is possible that the 
observed band is simply a small impurity that happens to be labeled by these mercury 
compounds. We think this is unlikely though, since heavy aggregation is expected when using 
this type of gel.  
 
Figure 41. Gel shift assay screening for heavy atom derivatization. Native PAGE analysis of C-
LptD-His8/LptE incubated with various heavy atom compounds. Red arrowhead shows 
migration of native protein (as judged by control); black arrowhead indicates slower migration.   
  Given these results, we soaked C-LptD-His8/LptE crystals with HgCl2 and screened them 
for diffraction. So far, the best data set that we have collected is at roughly 6 Å, but this was not 
sufficient to use for phasing the native data set.  
 
4.2.8. Crystallization with LPS additives 
  Given data showing that LPS may bind to LptE, we decided to co-crystallize C-LptD-
His8/LptE with a variety of purified LPS variants. These LPS variants were purified by Dorothee 
Andres and Carolin Doering from E. coli strains in which various LPS biosynthesis genes are 94 
 
knocked out. The structures of the LPS molecules used and the genes that are knocked out in the 
strains that produce them are shown below (Figure 42). When used as an additive in the 
condition that gave rise to the 3.85 Å data set, LPS from ΔlpxL and ΔrfaC strains led to crystals, 
but these crystals did not diffract well. While this strategy was not effective here, it might be 
worth revisiting if new conditions or constructs are found to give rise to diffracting crystals. It 
might also be worthwhile to screen for new conditions in the presence of these lipids.  
 
Figure 42. LPS additives used for co-crystallization screens. Crystals grew in the presence of 
LPS from ΔlpxL and ΔrfaC strains. Figure credit: Carolin Doering and Dorothee Andres.  
 
4.2.9. Discussion and future work 
  While the X-ray crystal structure of LptD/LptE has not yet been solved, we have made 
great progress in obtaining it. We modified the published purification protocol to obtain a purer 
sample in roughly double the yield. Then we identified a stable expression construct and used it 
to screen crystallization detergents under thousands of conditions. Once crystals were identified, 
we screened for additives that improved diffraction such that a useable data set could be 
obtained. Then we adopted two parallel strategies for obtaining phasing information. At this 
point a complete data set at 3.85 Å and a partial data set at 3.2 Å have been obtained, but phasing 
information is still missing.  95 
 
  Our top priority is to obtain phasing information for the data that we have. As such, we 
are primarily focusing on overexpressing SeMet substituted protein. We feel that the poor 
diffraction that was previously observed was due to the small size of the protein crystals as 
opposed to innately poor diffraction of the crystals. We previously observed a reliable correlation 
between LptD/LptE concentration and the size of the resulting protein crystal. Because of the 
low yield of SeMet substituted protein, we have been forced to set up crystallization experiments 
with protein concentrations of ~17 mg/ml, versus 30 mg/ml for native protein. We believe that 
by expressing more SeMet substituted protein we can overcome the yield issue and, hopefully, 
grow larger crystals. In addition to pursuing SeMet methods of phasing, we also plan to do 
additional screening with heavy atoms. The initial screening that was conducted lacked a control 
to ensure that the protein we were observing was LptD/LptE. This could be easily addressed by 
performing an α-LptD immunoblot using the native gel from the gel shift assay.  
  In addition to obtaining phasing information, it will likely be necessary to obtain a better 
diffracting data set. To do this, it will probably be necessary to find a better expression construct. 
One approach is to examine C-terminal truncations of LptE. As reported
105, E. coli LptE contains 
a C-terminal extension that is predicted to be unstructured. It was necessary to remove this 
region in order obtain diffracting crystals of E. coli LptE, and as such, its removal may benefit 
LptD/LptE crystallization and diffraction as well. Additionally, truncations at the LptD C-
terminus should also be explored since LptD secondary structure predictions suggest that there is 
likely an unstructured region at the LptD C-terminus as well. Removal of this extension could 
benefit both diffraction and crystallization. We have produced and purified several of these 
constructs already; conservative truncations such as C-LptDΔ760-784 overexpressed and purified 
well, while the more liberal truncation C-LptDΔ714-784 overexpressed but could not be pulled 96 
 
down with LptE-His6, suggesting that a portion of the β-barrel had been deleted, preventing 
interaction with LptE. It is worth noting that simultaneous removal of these C-terminal 
extensions from both LptE and LptD has the potential of interfering with affinity purification by 
causing the His-tag to be hidden. I have already observed this when trying to overexpress and 
purify C-LptD/LptEΔ168-193-His6. This construct overexpresses well, but only LptE is obtained 
following affinity purification, suggesting that either an unstable complex is formed or that 
interaction with C-LptD hides the affinity tag on LptE.  
  Another strategy that we have pursued is selective mutation of specific residues to reduce 
surface entropy in order to promote crystallization. According to software predictions (available 
at services.mbi.ucla.edu/SER/), mutation of K711 and Q712 to alanine is the change most critical 
to reducing surface entropy. We have generated this construct, but its expression has not yet been 
a priority. 
  We are also interested in crystallizing LptD/LptE homologues from species other than E. 
coli. LptD/LptE from P. aeruginosa is the most obvious choice as it is the target of an antibiotic. 
We have been able to overexpress and purify this protein complex, but its yield does not make its 
use in crystallography feasible at this point in time. We are also interested in trying to express 
LptD/LptE from other organisms as well, particularly from thermophilic organisms.  
  Overall, future efforts will initially focus on obtaining phasing information for our 
current data set and will then likely shift towards the screening of additional constructs, detergent 
mixtures, and conditions in order to obtain larger, better diffracting crystals.  
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4.3. Materials and Methods 
4.3.1. Strains and growth conditions 
  The strain BL21(λDE3) [F
- dcm ompT hsdS(r
-
Bm
-
B) gal(λDE3)] (Novagen) was initially 
used for protein overexpression. This strain was later modified to delete cyoA-E, as described 
below. Luria-Bertani (LB) broth and agar were prepared as described previously
135. Antibiotics 
were used at 50 µg/ml unless otherwise indicated. The strains primarily used for overexpression 
in this chapter are summarized in Table 3. 
 
Table 3. LptD/E expression strains used in this chapter.  
 
4.3.2. Deletion of cyoA-E 
  The genes cyoA-E were removed from the overexpression strain using a previously 
reported method of gene inactivation
144. Briefly, the kanamycin resistance gene, kan, was 
amplified via PCR from the pKD4 plasmid using primers CyoA-N-P1 and CyoE-C-P2 (Table 4). 
The resulting PCR product was gel purified and transformed via electroporation into 
BL21(λDE3) cells already bearing the plasmid pKD46. Cells of the resulting strain, bearing the 98 
 
cyoA-E::kan allele, were lysed with P1 phage, and the resulting lysate was used to transduce 
BL21(λDE3) cells, which were then subjected to kanamycin selection. Primers CyoA-F and 
CyoE-R (Table 4) were used in a test PCR to ensure the loss of cyoA-E.  
 
Table 4. Primers used in cyoA-E inactivation.  
 
4.3.3. Overexpression and purification of LptD/LptE 
  The appropriate overexpression strain (summarized in Table 3) was grown on LB-agar 
(supplemented with 50 µg/ml carbenicillin, 50 µg/ml streptomycin, 25 µg/ml kanamycin, and 
0.2% glucose) overnight at 37°C. Colonies from the plate were used to inoculate an appropriate 
number of 10 ml starter cultures (LB supplemented with 50 µg/ml carbenicillin, 50 µg/ml 
streptomycin, 25 µg/ml kanamycin, and 0.2% glucose), which were grown at 37°C until OD600 ~ 
0.6. At this point, 10 ml of starter culture was used to inoculate each 1.5 l culture (LB 
supplemented with 100 µg/ml carbenicillin, 50 µg/ml streptomycin, 25 µg/ml kanamycin, and 
0.2% glucose). The 1.5 l cultures were grown at 37°C with shaking at 220 rpm until OD600 ~ 
0.15, at which point the temperature was reduced to 26°C and the shaking speed was reduced to 
180 rpm. At OD600 ~ 0.6, 0.1 mM IPTG was added to each culture. The cultures were then 
grown for 20 hr. Cells were collected by centrifugation at 5,250 x g for 10 minutes, and the cells 
were resuspended in 30 ml of cold TBS (20 mM Tris-HCl, pH 8.0, 150 mM NaCl) 99 
 
(supplemented with 1 mM PMSF, 0.05 mg/ml DNase I, and 0.1 mg/ml lysozyme) per 1.5 l 
culture that was centrifuged. The resuspended cells were lysed by a single passage through a 
French Press (Thermo) at 16,000 psi, or by two passes through a cell disruptor (Avestin). The 
lysate was centrifuged for 10 min at 3,000 x g to remove unlysed cells, and the supernatant was 
centrifuged for 30 min at 100,000 x g in an ultracentrifuge (Model XL-90, Beckman; Type 45-Ti 
rotor). The supernatant was discarded, and the membrane pellet was resuspended in TBS-A (20 
mM Tris-HCl, pH 8.0, 300 mM NaCl, 20 mM imidazole) at a volume equal to half of what was 
centrifuged. Resuspended membranes were flash-frozen with liquid nitrogen and stored at -80°C 
for future use. To solubilize LptD/LptE, the frozen membranes were thawed, supplemented with 
1% LDAO (Anatrace, Sol-grade), and stirred at room temperature for 1.5 hr. Prior to screening 
for better solubilization conditions, 1% ZW3-14 (Anatrace) at 4°C was used instead. The 
solubilized membranes were then centrifuged again for 30 min at 100,000 x g in an 
ultracentrifuge (Model XL-90, Beckman; Type 45-Ti rotor). The supernatant was retained. For a 
purification that started with 45 l of culture, 16 ml of Ni-NTA resin (Qiagen), as a 50% slurry, 
was used for affinity purification. The resin slurry was applied to a column, allowed to drain by 
gravity, and washed with 100 ml of TBS-A supplemented with 0.1% LDAO. The supernatant 
from the membrane solubilization was applied to the column and allowed to drain by gravity. 
The flow-through was reapplied to the column and drained again. The column was washed four 
times with a total of 200 ml of TBS-A (supplemented with the detergent to be used for 
crystallization, typically either 0.8% C8E4 (Bachem) or 1% OG (Antrace)). Other 
detergents/additives were used on occasion, and include C8E5 (Anatrace), Fos-12 (Anatrace), 
DDM (Anatrace), and heptane-1,2,3-triol (Sigma). The protein was eluted in 40 ml of TBS-B (20 
mM Tris-HCl, pH 8.0, 150 mM NaCl, 200 mM imidazole) (supplemented with the same 100 
 
detergent present in the wash buffer). Protein was concentrated in an ultrafiltration device 
(Amicon Ultra, Millipore, 50 kDa cut-off) and further purified by SEC using a pre-packed 
Superdex 200 column (GE Healthcare), using 10 mM HEPES pH 7.5, 150 mM NaCl, 
supplemented with the appropriate detergent, as the eluent. Protein concentration was determined 
by NanoDrop spectrophotometer (Thermo, A280 measurement). Protein concentration was 
calculated using extinction coefficients as determined by ExPASy ProtParam tool (available at 
web.expasy.org/protparam/). SDS-PAGE was performed using 4-20% Tris-HCl polyacrylamide 
gels as previously published
140. Gels were run at 150 V for 1 hr. Lysine methylation, when 
performed, was done as described in Chapter 3.  
 
4.3.4. Overexpression and purification of LptD/E mutants 
  LptD4213 and LptE6 were overexpressed from the appropriate strains, as described in 
Table 3. Overexpression and purification for these mutants was carried out as described above. 
These complexes were solubilized with ZW3-14 and ultimately purified in 1% OG, as described 
earlier. Seminative SDS-PAGE was conducted using 4-20% Tris-HCl polyacrylamide gels. 
These samples were either heated or not. The gel was ran at 4°C for 2 hr at 120 V. 
  Trypsin digestion was performed in five separate 20 µl reactions containing 1 mg/ml 
purified protein and either 0, 0.05, 0.5, 5, or 50 µg/ml trypsin. The digestion reactions were 
incubated at room temperature for 3 hr, after which time 20 µl of 2x SDS loading dye was added 
to each reaction and the sample was immediately heated. The reactions were then analyzed by 
SDS-PAGE, as described above. 
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4.3.5. Plasmid construction 
  pET23/42lptD, pET23/42ClptD, pET23/42ClptD-His8, pCDFlptE, and pCDFlptE-His6 
have been previously reported
105. Site-directed mutagenesis was used to generate LptD C-
terminal truncation and LptD surface entropy reduction constructs using primers from Table 5 
and pET23/42ClptD as the initial template. Briefly, the entire template was amplified by PCR 
and the resulting PCR product mixture digested with DpnI for >1 h at 37°C. NovaBlue 
(Novagen) cells were transformed with 1 μl of digested PCR product and plated onto LB plates 
containing 50 μg/ml carbenicillin. For each construct, plasmids from six colonies were isolated 
and sequenced. 
 
Table 5. Primers used to construct plasmids encoding C-terminally truncated lptD and surface 
entropy reduction mutants of lptD. 
 
 
4.3.6. Crystallization 
  For screening of crystallization conditions, purified protein was prepared as above and 
concentrated to an appropriate concentration (generally 10-35 mg/ml). The protein sample was 
dispensed using a Formulatrix NT8 drop-setting robot into 96-well sitting drop crystallization 102 
 
plates (MRC 3 well crystallization plate, Swissci). Crystallization droplets contained 150 nl 
protein and 150 nl precipitant solution, and the reservoir solution contained 30 µl of the 
precipitant solution. The following crystallization screens were routinely used: Clear Strategy I 
and II, MemGold I and II, and MemPlus (all from Molecular Dimensions). Plates were stored at 
either 4°C or 19°C and imaged in a crystallization hotel (Formulatrix).  
  Larger scale crystallization was set by hand in 24-well sitting drop Cryschem 
crystallization plates (Hampton). The precipitant solution was made by hand from individual 
components. The reservoir of each well was filled with 750 µl of the precipitant solution. 
Various droplet volumes were used; 1 µl to 1 µl,  2 µl to 2 µl, 1 µl to 2 µl, 2 µl to 1 µl, 1 µl to 3 
µl, and 3 µl to 1 µl of protein to precipitant were used. Grid-like variation of the precipitant 
condition was typically done when scaling up crystallization experiments (e.g. using more or less 
PEG in 1% steps).  
  Additive screening was conducted using an additive screen from Hampton Research in a 
96 well fashion, as described above. The additive screen was mixed 1:10 with 400 mM KSCN, 
100 mM sodium acetate, pH 4.5, and either 11% or 15% PEG 4K to form the precipitant for the 
condition being screened. When LPS molecules were used as additives, they were added at 
concentration of 10 mM, with the exception of Lipid A (1 mM), wild-type LPS (10 mg/ml), and 
LPS from ΔlpxL (1 mM). 
  The MemMagic Bicelle Screen Kit (Molecular Dimensions) was used when screening 
bicelle solubilized protein. In short, OG or C8E4 solubilized protein was mixed 4:1 with either 
40%, 35%, 30%, or 25% DMPC:CHAPSO (2.8:1) and incubated on ice for at least 30 minutes 
prior to pipetting. 25% bicelles was used for the crystals that yielded the 3.85 Å data set.  103 
 
  Crystals were cryoprotected by gradual addition of a cryoprotectant solution consisting of 
1% C8E4, 70 mM acid acid/NaOH pH 4.5, 0.42 M KSCN, 7% PEG 4K, and 30% glycerol. 
Crystals were mounted into loops and frozen by direct immersion into liquid nitrogen.  
 
4.3.7. Collection of diffraction data 
  Screening for X-ray diffraction and collection of diffraction data occurred at Brookhaven 
National Laboratory National Synchrotron Light Source II (NSLS-II), Argonne National 
Laboratory Advanced Photon Source (APS), and Lawrence Berkeley National Laboratory 
Advanced Light Source (ALS).  
 
4.3.8. Data processing and molecular replacement 
X-ray diffraction data were integrated using MOSFLM
145 and scaled using SCALA
146. 
Subsequently, molecular replacement was run using Phaser
147 within the CCP4 crystallographic 
software suite
148.  
 
4.3.9. Production of selenomethionine labeled protein 
  M9 minimal media was used for overexpression of selenomethionine labeled protein. It is 
prepared by first preparing 5x M9 salts by dissolving 256 g Na2HPO4·7H2O, 60 g KH2PO4, 10 g 
NaCl, and 20 g NH4Cl in 4 l deionized water. 300 ml of 5x M9 salts is diluted to 1.5 l in a 4 l 
flask and autoclaved. Once cool, and when ready for use, it is supplemented with 0.4% glucose, 
2 mM MgSO4, 0.1 mM CaCl2, vitamins, and trace metals. The vitamin solution is prepared as a 
1000x stock solution by dissolving 0.5 g riboflavin, 0.5 g niacin, 0.5 pyridoxine monohydrate, 
and 0.5 g thiamine in 500 ml water. The trace metals solution is prepared as a 100x stock by 104 
 
dissolving 5 g EDTA, 0.8 g FeCl3, 0.05 g ZnCl2, 0.01 g CuCl2, 0.01 g CoCl2, 0.01 g HBO3, 1.6 g 
MnCl2, 0.01 g Ni2SO4, and 0.01 g molybdic acid in 1 l deionized water (in that order) and 
adjusting the pH to 7.0 with NaOH. Glucose, CaCl2, MgSO4, vitamins, and trace metal stock 
solutions all must be sterile filtered prior to use.  
The overexpression of selenomethionine labeled protein was adapted from previously 
reported protocols
149. The BL21(λDE3) ΔcyoA-E::kan pET23/42ClptD-His8 pCDFlptE strain 
was grown on LB-agar (supplemented with 50 µg/ml carbenicillin, 50 µg/ml streptomycin, 25 
µg/ml kanamycin, and 0.2% glucose) overnight at 37°C. Colonies from the plate were used to 
inoculate an appropriate number of 10 ml starter cultures (M9 minimum medium, supplemented 
with glucose, MgSO4, vitamins, trace metals, CaCl2, 50 µg/ml carbenicillin, 50 µg/ml 
streptomycin, and 25 µg/ml kanamycin), which were grown at 37°C until OD600 ~ 0.6. At this 
point, 10 ml of starter culture was used to inoculate each 1.5 l culture (M9 minimum medium, 
supplemented with glucose, MgSO4, vitamins, trace metals, CaCl2, 100 µg/ml carbenicillin, 50 
µg/ml streptomycin, and 25 µg/ml kanamycin). The 1.5 l cultures were grown at 37°C with 
shaking at 220 rpm until OD600 ~ 0.15, at which point the temperature was reduced to 26°C and 
the shaking speed was reduced to 180 rpm. At OD600 ~ 0.3, 0.15 g L-lysine (Sigma), 0.15 g L-
threonine (Sigma), 0.15 g L-phenylalanine (Sigma), 0.075 g L-leucine (Sigma), 0.075 g L-
isoleucine (Sigma), 0.075 g L-valine (Sigma), and 0.075 g L-selenomethonine (Tokyo Chemical 
Industry Co., TCI) were individually added to each 1.5 l culture. At OD600 ~ 0.6, and at least 30 
minutes following amino acid addition, 0.1 mM IPTG was added to each culture. The cultures 
were then grown for 20 hr and processed as usual.  
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4.3.10. Heavy atom screening 
  The gel shift assay was conducted as previously reported
150. In brief, 35 mg/ml protein 
was incubated in 10 µl reactions with 5 mM heavy atom compound in the dark for 2 hr. The 
heavy atom compounds were prepared freshly as a 50 mM stock solution in the same buffer as 
the protein. All heavy atom compounds were from heavy atom screens available from Hampton 
Research. 1 mM DTT was added to reactions containing mercury in order to assure that the 
cysteine residues were reduced. 4 µl from each reaction was combined with 4 µl native gel 
loading buffer (62 mM Tris-HCl, pH 6.8, 1% bromophenol blue, 25% glycerol, 0.8% C8E4). The 
samples were run on 4-20% gradient acrylamide gels for 3 hours at 150 V at 4°C. The gel 
running buffer was supplemented with detergent (25 mM Tris-base, 192 mM Glycine, 0.8% 
C8E4).  
  Heavy atom derivatives of LptD/E crystals were produced by adding a solution 
containing 1 mM TCEP for 5 min followed by 5 mM HgCl2 for 15 minutes. Both solutes were 
freshly prepared and were dissolved in a cryoprotectant solution consisting of 1% C8E4, 70 mM 
acetic acid/NaOH pH 4.5, 0.42 mM KSCN, 7% PEG 4K, and 30% glycerol. Crystals were then 
mounted into loops and frozen by direct immersion in liquid nitrogen.  
   106 
 
 
References 
 
1  Gan, L., Chen, S. & Jensen, G. J. Molecular organization of Gram-negative 
peptidoglycan. Proceedings of the National Academy of Sciences of the United States of 
America 105, 18953-18957, doi:10.1073/pnas.0808035105 (2008). 
2  Vollmer, W. & Holtje, J. V. The architecture of the murein (peptidoglycan) in gram-
negative bacteria: vertical scaffold or horizontal layer(s)? Journal of bacteriology 186, 
5978-5987, doi:10.1128/JB.186.18.5978-5987.2004 (2004). 
3  Nikaido, H. Molecular Basis of Bacterial Outer Membrane Permeability Revisited. 
Microbiology and Molecular Biology Reviews 67, 593-656, doi:10.1128/mmbr.67.4.593-
656.2003 (2003). 
4  Raetz, C. R. & Whitfield, C. Lipopolysaccharide endotoxins. Annual review of 
biochemistry 71, 635-700, doi:10.1146/annurev.biochem.71.110601.135414 (2002). 
5  Plesiat, P. & Nikaido, H. Outer membranes of Gram‐negative bacteria are permeable to 
steroid probes. Molecular microbiology 6, 1323-1333 (1992). 
6  Plesiat, P., Aires, J. R., Godard, C. & Köhler, T. Use of steroids to monitor alterations in 
the outer membrane of Pseudomonas aeruginosa. Journal of bacteriology 179, 7004-7010 
(1997). 
7  Raetz, C. R. Biochemistry of endotoxins. Annual review of biochemistry 59, 129-170 
(1990). 
8  Poltorak, A. Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations 
in Tlr4 Gene. Science 282, 2085-2088, doi:10.1126/science.282.5396.2085 (1998). 
9  Hoshino, K. et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are 
hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. The 
Journal of Immunology 162, 3749-3752 (1999). 
10  MÜHLRADT, P. F. & GOLECKI, J. R. Asymmetrical distribution and artifactual 
reorientation of lipopolysaccharide in the outer membrane bilayer of Salmonella 
typhimurium. European Journal of Biochemistry 51, 343-352 (1975). 
11  Kamio, Y. & Nikaido, H. Outer membrane of Salmonella typhimurium: accessibility of 
phospholipid head groups to phospholipase c and cyanogen bromide activated dextran in 
the external medium. Biochemistry 15, 2561-2570 (1976). 
12  Funahara, Y. & Nikaido, H. Asymmetric localization of lipopolysaccharides on the outer 
membrane of Salmonella typhimurium. Journal of bacteriology 141, 1463-1465 (1980). 107 
 
13  Bos, M. P., Robert, V. & Tommassen, J. Biogenesis of the gram-negative bacterial outer 
membrane. Annual review of microbiology 61, 191-214, 
doi:10.1146/annurev.micro.61.080706.093245 (2007). 
14  Suzuki, H. et al. Murein-lipoprotein of Escherichia coli: a protein involved in the 
stabilization of bacterial cell envelope. Molecular and General Genetics MGG 167, 1-9 
(1978). 
15  Cascales, E., Bernadac, A., Gavioli, M., Lazzaroni, J. C. & Lloubes, R. Pal Lipoprotein 
of Escherichia coli Plays a Major Role in Outer Membrane Integrity. Journal of 
bacteriology 184, 754-759, doi:10.1128/jb.184.3.754-759.2002 (2002). 
16  Ruiz, N., Kahne, D. & Silhavy, T. J. Transport of lipopolysaccharide across the cell 
envelope: the long road of discovery. Nature reviews. Microbiology 7, 677-683, 
doi:10.1038/nrmicro2184 (2009). 
17  Schulz, G. E. The structure of bacterial outer membrane proteins. Biochimica et 
Biophysica Acta (BBA) - Biomembranes 1565, 308-317, 
doi:http://dx.doi.org/10.1016/S0005-2736(02)00577-1 (2002). 
18  Malinverni, J. C. & Silhavy, T. J. An ABC transport system that maintains lipid 
asymmetry in the gram-negative outer membrane. Proceedings of the National Academy 
of Sciences of the United States of America 106, 8009-8014, 
doi:10.1073/pnas.0903229106 (2009). 
19  Lugtenberg, E. & Peters, R. Distribution of lipids in cytoplasmic and outer membranes 
of< i> Escherichia coli</i> K12. Biochimica et Biophysica Acta (BBA)-Lipids and Lipid 
Metabolism 441, 38-47 (1976). 
20  ISHINAGA, M. & KANAMOTO, R. Distribution of phospholipid molecular species in 
outer and cytoplasmic membranes of Escherichia coli. Journal of biochemistry 86, 161-
165 (1979). 
21  White, D. A., Lennarz, W. & Schnaitman, C. A. Distribution of lipids in the wall and 
cytoplasmic membrane subfractions of the cell envelope of Escherichia coli. Journal of 
bacteriology 109, 686-690 (1972). 
22  Tefsen, B., Geurtsen, J., Beckers, F., Tommassen, J. & de Cock, H. Lipopolysaccharide 
transport to the bacterial outer membrane in spheroplasts. The Journal of biological 
chemistry 280, 4504-4509, doi:10.1074/jbc.M409259200 (2005). 
23  Jones, N. C. & Osborn, M. Translocation of phospholipids between the outer and inner 
membranes of Salmonella typhimurium. Journal of Biological Chemistry 252, 7405-7412 
(1977). 
24  Langley, K., Hawrot, E. & Kennedy, E. Membrane assembly: movement of 
phosphatidylserine between the cytoplasmic and outer membranes of Escherichia coli. 
Journal of bacteriology 152, 1033-1041 (1982). 108 
 
25  Donohue-Rolfe, A. M. & Schaechter, M. Translocation of phospholipids from the inner 
to the outer membrane of Escherichia coli. Proceedings of the National Academy of 
Sciences 77, 1867-1871 (1980). 
26  Papanikou, E., Karamanou, S. & Economou, A. Bacterial protein secretion through the 
translocase nanomachine. Nature reviews. Microbiology 5, 839-851, 
doi:10.1038/nrmicro1771 (2007). 
27  Tokuda, H. Biogenesis of Outer Membranes in Gram-Negative Bacteria. Bioscience, 
Biotechnology, and Biochemistry 73, 465-473, doi:10.1271/bbb.80778 (2009). 
28  Yamaguchi, K., Yu, F. & Inouye, M. A single amino acid determinant of the membrane 
localization of lipoproteins in E. coli. Cell 53, 423-432 (1988). 
29  Gennity, J. M. & Inouye, M. The protein sequence responsible for lipoprotein membrane 
localization in Escherichia coli exhibits remarkable specificity. Journal of Biological 
Chemistry 266, 16458-16464 (1991). 
30  Seydel, A., Gounon, P. & Pugsley, A. P. Testing the „+ 2 rule‟for lipoprotein sorting in 
the Escherichia coli cell envelope with a new genetic selection. Molecular microbiology 
34, 810-821 (1999). 
31  Terada, M., Kuroda, T., Matsuyama, S. I. & Tokuda, H. Lipoprotein sorting signals 
evaluated as the LolA-dependent release of lipoproteins from the cytoplasmic membrane 
of Escherichia coli. The Journal of biological chemistry 276, 47690-47694, 
doi:10.1074/jbc.M109307200 (2001). 
32  Matsuyama, S., Tajima, T. & Tokuda, H. A novel periplasmic carrier protein involved in 
the sorting and transport of Escherichia coli lipoproteins destined for the outer 
membrane. The EMBO journal 14, 3365 (1995). 
33  Matsuyama, S. i., Yokota, N. & Tokuda, H. A novel outer membrane lipoprotein, LolB 
(HemM), involved in the LolA (p20)‐dependent localization of lipoproteins to the outer 
membrane of Escherichia coli. The EMBO journal 16, 6947-6955 (1997). 
34  Yakushi, T. LolA-dependent Release of a Lipid-modified Protein from the Inner 
Membrane of Escherichia coli Requires Nucleoside Triphosphate. Journal of Biological 
Chemistry 273, 32576-32581, doi:10.1074/jbc.273.49.32576 (1998). 
35  Yakushi, T., Masuda, K., Narita, S.-i., Matsuyama, S.-i. & Tokuda, H. A new ABC 
transporter mediating the detachment of lipid-modified proteins from membranes. Nature 
cell biology 2, 212-218 (2000). 
36  Masuda, K., Matsuyama, S. & Tokuda, H. Elucidation of the function of lipoprotein-
sorting signals that determine membrane localization. Proceedings of the National 
Academy of Sciences of the United States of America 99, 7390-7395, 
doi:10.1073/pnas.112085599 (2002). 109 
 
37  Hara, T., Matsuyama, S. & Tokuda, H. Mechanism underlying the inner membrane 
retention of Escherichia coli lipoproteins caused by Lol avoidance signals. The Journal of 
biological chemistry 278, 40408-40414, doi:10.1074/jbc.M307836200 (2003). 
38  Fukuda, A. et al. Aminoacylation of the N-terminal cysteine is essential for Lol-
dependent release of lipoproteins from membranes but does not depend on lipoprotein 
sorting signals. The Journal of biological chemistry 277, 43512-43518, 
doi:10.1074/jbc.M206816200 (2002). 
39  Yokota, N., Kuroda, T., Matsuyama, S.-i. & Tokuda, H. Characterization of the LolA-
LolB system as the general lipoprotein localization mechanism of Escherichia coli. 
Journal of Biological Chemistry 274, 30995-30999 (1999). 
40  Takeda, K. et al. Crystal structures of bacterial lipoprotein localization factors, LolA and 
LolB. The EMBO journal 22, 3199-3209 (2003). 
41  Okuda, S. & Tokuda, H. Model of mouth-to-mouth transfer of bacterial lipoproteins 
through inner membrane LolC, periplasmic LolA, and outer membrane LolB. 
Proceedings of the National Academy of Sciences of the United States of America 106, 
5877-5882, doi:10.1073/pnas.0900896106 (2009). 
42  Taniguchi, N., Matsuyama, S. & Tokuda, H. Mechanisms underlying energy-independent 
transfer of lipoproteins from LolA to LolB, which have similar unclosed {beta}-barrel 
structures. The Journal of biological chemistry 280, 34481-34488, 
doi:10.1074/jbc.M507388200 (2005). 
43  Knowles, T. J., Scott-Tucker, A., Overduin, M. & Henderson, I. R. Membrane protein 
architects: the role of the BAM complex in outer membrane protein assembly. Nature 
reviews. Microbiology 7, 206-214, doi:10.1038/nrmicro2069 (2009). 
44  Kim, K. H., Aulakh, S. & Paetzel, M. The bacterial outer membrane beta-barrel assembly 
machinery. Protein science : a publication of the Protein Society 21, 751-768, 
doi:10.1002/pro.2069 (2012). 
45  Sklar, J. G., Wu, T., Kahne, D. & Silhavy, T. J. Defining the roles of the periplasmic 
chaperones SurA, Skp, and DegP in Escherichia coli. Genes & development 21, 2473-
2484, doi:10.1101/gad.1581007 (2007). 
46  Volokhina, E. B. et al. Role of the periplasmic chaperones Skp, SurA, and DegQ in outer 
membrane protein biogenesis in Neisseria meningitidis. Journal of bacteriology 193, 
1612-1621, doi:10.1128/JB.00532-10 (2011). 
47  Wu, T. et al. Identification of a Multicomponent Complex Required for Outer Membrane 
Biogenesis in< i> Escherichia coli</i>. Cell 121, 235-245 (2005). 
48  Voulhoux, R., Bos, M. P., Geurtsen, J., Mols, M. & Tommassen, J. Role of a highly 
conserved bacterial protein in outer membrane protein assembly. Science 299, 262-265 
(2003). 110 
 
49  Werner, J. & Misra, R. YaeT (Omp85) affects the assembly of lipid‐dependent and lipid‐
independent outer membrane proteins of Escherichia coli. Molecular microbiology 57, 
1450-1459 (2005). 
50  Doerrler, W. T. & Raetz, C. R. Loss of outer membrane proteins without inhibition of 
lipid export in an Escherichia coli YaeT mutant. Journal of Biological Chemistry 280, 
27679-27687 (2005). 
51  Bos, M. P., Tefsen, B., Geurtsen, J. & Tommassen, J. Identification of an outer 
membrane protein required for the transport of lipopolysaccharide to the bacterial cell 
surface. Proceedings of the National Academy of Sciences of the United States of 
America 101, 9417-9422 (2004). 
52  Sánchez-Pulido, L., Devos, D., Genevrois, S., Vicente, M. & Valencia, A. POTRA: a 
conserved domain in the FtsQ family and a class of β-barrel outer membrane proteins. 
Trends in biochemical sciences 28, 523-526 (2003). 
53  Kim, S. et al. Structure and function of an essential component of the outer membrane 
protein assembly machine. Science 317, 961-964 (2007). 
54  Knowles, T. J. et al. Fold and function of polypeptide transport‐associated domains 
responsible for delivering unfolded proteins to membranes. Molecular microbiology 68, 
1216-1227 (2008). 
55  Hagan, C. L., Kim, S. & Kahne, D. Reconstitution of outer membrane protein assembly 
from purified components. Science 328, 890-892, doi:10.1126/science.1188919 (2010). 
56  Hagan, C. L., Westwood, D. B. & Kahne, D. Bam lipoproteins assemble BamA in vitro. 
Biochemistry 52, 6108-6113 (2013). 
57  Hagan, C. L. & Kahne, D. The reconstituted Escherichia coli Bam complex catalyzes 
multiple rounds of β-barrel assembly. Biochemistry 50, 7444-7446 (2011). 
58  Noinaj, N. et al. Structural insight into the biogenesis of [bgr]-barrel membrane proteins. 
Nature 501, 385-390 (2013). 
59  Anderson, M. S. & Raetz, C. Biosynthesis of lipid A precursors in Escherichia coli. A 
cytoplasmic acyltransferase that converts UDP-N-acetylglucosamine to UDP-3-O-(R-3-
hydroxymyristoyl)-N-acetylglucosamine. Journal of Biological Chemistry 262, 5159-
5169 (1987). 
60  Anderson, M. S., Bulawa, C. E. & Raetz, C. The biosynthesis of gram-negative 
endotoxin. Formation of lipid A precursors from UDP-GlcNAc in extracts of Escherichia 
coli. Journal of Biological Chemistry 260, 15536-15541 (1985). 
61  Anderson, M. et al. UDP-N-acetylglucosamine acyltransferase of Escherichia coli. The 
first step of endotoxin biosynthesis is thermodynamically unfavorable. Journal of 
Biological Chemistry 268, 19858-19865 (1993). 111 
 
62  Anderson, M. S., Robertson, A. D., Macher, I. & Raetz, C. R. Biosynthesis of lipid A in 
Escherichia coli: identification of UDP-3-O-[(R)-3-hydroxymyristoyl]-. alpha.-D-
glucosamine as a precursor of UDP-N2, O3-bis [(R)-3-hydroxymyristoyl]-. alpha.-D-
glucosamine. Biochemistry 27, 1908-1917 (1988). 
63  Young, K. et al. The envA permeability/cell division gene of Escherichia coli encodes the 
second enzyme of lipid A biosynthesis UDP-3-O-(R-3-hydroxymyristoyl)-N-
acetylglucosamine deacetylase. Journal of Biological Chemistry 270, 30384-30391 
(1995). 
64  Kelly, T., Stachula, S., Raetz, C. & Anderson, M. The firA gene of Escherichia coli 
encodes UDP-3-O-(R-3-hydroxymyristoyl)-glucosamine N-acyltransferase. The third 
step of endotoxin biosynthesis. Journal of Biological Chemistry 268, 19866-19874 
(1993). 
65  Babinski, K. J., Kanjilal, S. J. & Raetz, C. R. Accumulation of the lipid A precursor 
UDP-2, 3-diacylglucosamine in an Escherichia coli mutant lacking the lpxH gene. 
Journal of Biological Chemistry 277, 25947-25956 (2002). 
66  Babinski, K. J., Ribeiro, A. A. & Raetz, C. R. The Escherichia coli gene encoding the 
UDP-2, 3-diacylglucosamine pyrophosphatase of lipid A biosynthesis. Journal of 
Biological Chemistry 277, 25937-25946 (2002). 
67  Metzger IV, L. E. & Raetz, C. R. Purification and characterization of the lipid A 
disaccharide synthase (LpxB) from Escherichia coli, a peripheral membrane protein. 
Biochemistry 48, 11559-11571 (2009). 
68  Ray, B. & Raetz, C. The biosynthesis of gram-negative endotoxin. A novel kinase in 
Escherichia coli membranes that incorporates the 4'-phosphate of lipid A. Journal of 
Biological Chemistry 262, 1122-1128 (1987). 
69  Garrett, T. A., Kadrmas, J. L. & Raetz, C. R. Identification of the Gene Encoding the 
Escherichia coli Lipid A 4′-Kinase FACILE PHOSPHORYLATION OF ENDOTOXIN 
ANALOGS WITH RECOMBINANT LpxK. Journal of Biological Chemistry 272, 
21855-21864 (1997). 
70  Clementz, T. & Raetz, C. A gene coding for 3-deoxy-D-manno-octulosonic-acid 
transferase in Escherichia coli. Identification, mapping, cloning, and sequencing. Journal 
of Biological Chemistry 266, 9687-9696 (1991). 
71  Belunis, C. & Raetz, C. Biosynthesis of endotoxins. Purification and catalytic properties 
of 3-deoxy-D-manno-octulosonic acid transferase from Escherichia coli. Journal of 
Biological Chemistry 267, 9988-9997 (1992). 
72  Six, D. A., Carty, S. M., Guan, Z. & Raetz, C. R. Purification and Mutagenesis of LpxL, 
the Lauroyltransferase of Escherichia coli Lipid A Biosynthesis†. Biochemistry 47, 8623-
8637 (2008). 112 
 
73  Brozek, K. A. & Raetz, C. Biosynthesis of lipid A in Escherichia coli. Acyl carrier 
protein-dependent incorporation of laurate and myristate. Journal of Biological 
Chemistry 265, 15410-15417 (1990). 
74  Meredith, T. C., Aggarwal, P., Mamat, U., Lindner, B. & Woodard, R. W. Redefining the 
requisite lipopolysaccharide structure in Escherichia coli. ACS chemical biology 1, 33-42 
(2006). 
75  Mamat, U. et al. Single amino acid substitutions in either YhjD or MsbA confer viability 
to 3‐deoxy‐d‐manno‐oct‐2‐ulosonic acid‐depleted Escherichia coli. Molecular 
microbiology 67, 633-648 (2008). 
76  Klein, G., Lindner, B., Brabetz, W., Brade, H. & Raina, S. Escherichia coli K-12 
Suppressor-free Mutants Lacking Early Glycosyltransferases and Late Acyltransferases 
MINIMAL LIPOPOLYSACCHARIDE STRUCTURE AND INDUCTION OF 
ENVELOPE STRESS RESPONSE. Journal of biological chemistry 284, 15369-15389 
(2009). 
77  Wang, X. & Quinn, P. J. Lipopolysaccharide: Biosynthetic pathway and structure 
modification. Progress in lipid research 49, 97-107, doi:10.1016/j.plipres.2009.06.002 
(2010). 
78  Roncero, C. & Casadaban, M. J. Genetic analysis of the genes involved in synthesis of 
the lipopolysaccharide core in Escherichia coli K-12: three operons in the rfa locus. 
Journal of bacteriology 174, 3250-3260 (1992). 
79  Schnaitman, C. A. & Klena, J. D. Genetics of lipopolysaccharide biosynthesis in enteric 
bacteria. Microbiological reviews 57, 655-682 (1993). 
80  Brozek, K. A., Hosaka, K., Robertson, A. & Raetz, C. Biosynthesis of lipopolysaccharide 
in Escherichia coli. Cytoplasmic enzymes that attach 3-deoxy-D-manno-octulosonic acid 
to lipid A. Journal of Biological Chemistry 264, 6956-6966 (1989). 
81  Whitfield, C. & Amor, P. A. Modulation of the surface architecture of Gram‐negative 
bacteria by the action of surface polymer: lipid A–core ligase and by determinants of 
polymer chain length. Molecular microbiology 23, 629-638 (1997). 
82  Abeyrathne, P. D., Daniels, C., Poon, K. K., Matewish, M. J. & Lam, J. S. Functional 
characterization of WaaL, a ligase associated with linking O-antigen polysaccharide to 
the core of Pseudomonas aeruginosa lipopolysaccharide. Journal of bacteriology 187, 
3002-3012 (2005). 
83  Wösten, M. M., Kox, L. F., Chamnongpol, S., Soncini, F. C. & Groisman, E. A. A signal 
transduction system that responds to extracellular iron. Cell 103, 113-125 (2000). 
84  Guo, L. et al. Regulation of lipid A modifications by Salmonella typhimurium virulence 
genes phoP-phoQ. Science 276, 250-253 (1997). 113 
 
85  Soncini, F. C., Vescovi, E. G., Solomon, F. & Groisman, E. A. Molecular basis of the 
magnesium deprivation response in Salmonella typhimurium: identification of PhoP-
regulated genes. Journal of bacteriology 178, 5092-5099 (1996). 
86  Gunn, J. S., Ryan, S. S., Van Velkinburgh, J. C., Ernst, R. K. & Miller, S. I. Genetic and 
Functional Analysis of a PmrA-PmrB-Regulated Locus Necessary for 
Lipopolysaccharide Modification, Antimicrobial Peptide Resistance, and Oral Virulence 
of Salmonella entericaSerovar Typhimurium. Infection and immunity 68, 6139-6146 
(2000). 
87  Breazeale, S. D., Ribeiro, A. A. & Raetz, C. R. Oxidative Decarboxylation of UDP-
Glucuronic Acid in Extracts of Polymyxin-resistant Escherichia coli ORIGIN OF LIPID 
A SPECIES MODIFIED WITH 4-AMINO-4-DEOXY-l-ARABINOSE. Journal of 
Biological Chemistry 277, 2886-2896 (2002). 
88  Gatzeva-Topalova, P. Z., May, A. P. & Sousa, M. C. Crystal structure of Escherichia coli 
ArnA (PmrI) decarboxylase domain. A key enzyme for lipid A modification with 4-
amino-4-deoxy-L-arabinose and polymyxin resistance. Biochemistry 43, 13370-13379 
(2004). 
89  Groisman, E. A., Kayser, J. & Soncini, F. C. Regulation of polymyxin resistance and 
adaptation to low-Mg2+ environments. Journal of bacteriology 179, 7040-7045 (1997). 
90  Roland, K. L., Martin, L. E., Esther, C. R. & Spitznagel, J. K. Spontaneous pmrA 
mutants of Salmonella typhimurium LT2 define a new two-component regulatory system 
with a possible role in virulence. Journal of bacteriology 175, 4154-4164 (1993). 
91  Wang, X., Ribeiro, A. A., Guan, Z., Abraham, S. N. & Raetz, C. R. Attenuated virulence 
of a Francisella mutant lacking the lipid A 4′-phosphatase. Proceedings of the National 
Academy of Sciences 104, 4136-4141 (2007). 
92  Ahn, V. E. et al. A hydrocarbon ruler measures palmitate in the enzymatic acylation of 
endotoxin. The EMBO journal 23, 2931-2941 (2004). 
93  Kawasaki, K., Ernst, R. K. & Miller, S. I. 3-O-deacylation of lipid A by PagL, a 
PhoP/PhoQ-regulated deacylase of Salmonella typhimurium, modulates signaling 
through Toll-like receptor 4. Journal of Biological Chemistry 279, 20044-20048 (2004). 
94  Gibbons, H. S., Lin, S., Cotter, R. J. & Raetz, C. R. Oxygen Requirement for the 
Biosynthesis of theS-2-Hydroxymyristate Moiety in Salmonella typhimurium Lipid A 
FUNCTION OF LpxO, A NEW Fe2+/α-KETOGLUTARATE-DEPENDENT 
DIOXYGENASE HOMOLOGUE. Journal of Biological Chemistry 275, 32940-32949 
(2000). 
95  Doerrler, W. T., Gibbons, H. S. & Raetz, C. R. MsbA-dependent translocation of lipids 
across the inner membrane of Escherichia coli. Journal of Biological Chemistry 279, 
45102-45109 (2004). 114 
 
96  Karow, M. & Georgopoulos, C. The essential Escherichia coli msbA gene, a multicopy 
suppressor of null mutations in the htrB gene, is related to the universally conserved 
family of ATP‐dependent translocators. Molecular microbiology 7, 69-79 (1993). 
97  Zhou, Z., White, K. A., Polissi, A., Georgopoulos, C. & Raetz, C. R. Function of 
Escherichia coli MsbA, an essential ABC family transporter, in lipid A and phospholipid 
biosynthesis. Journal of Biological Chemistry 273, 12466-12475 (1998). 
98  Doerrler, W. T. & Raetz, C. R. ATPase activity of the MsbA lipid flippase of Escherichia 
coli. Journal of Biological Chemistry 277, 36697-36705 (2002). 
99  Ward, A., Reyes, C. L., Yu, J., Roth, C. B. & Chang, G. Flexibility in the ABC 
transporter MsbA: Alternating access with a twist. Proceedings of the National Academy 
of Sciences 104, 19005-19010 (2007). 
100  Zou, P. & Mchaourab, H. S. Alternating access of the putative substrate-binding chamber 
in the ABC transporter MsbA. Journal of molecular biology 393, 574-585 (2009). 
101  Zou, P., Bortolus, M. & Mchaourab, H. S. Conformational cycle of the ABC transporter 
MsbA in liposomes: detailed analysis using double electron–electron resonance 
spectroscopy. Journal of molecular biology 393, 586-597 (2009). 
102  Ruiz, N., Gronenberg, L. S., Kahne, D. & Silhavy, T. J. Identification of two inner-
membrane proteins required for the transport of lipopolysaccharide to the outer 
membrane of Escherichia coli. Proceedings of the National Academy of Sciences of the 
United States of America 105, 5537-5542, doi:10.1073/pnas.0801196105 (2008). 
103  Freinkman, E., Okuda, S., Ruiz, N. & Kahne, D. Regulated assembly of the 
transenvelope protein complex required for lipopolysaccharide export. Biochemistry 51, 
4800-4806 (2012). 
104  Wu, T. et al. Identification of a protein complex that assembles lipopolysaccharide in the 
outer membrane of Escherichia coli. Proceedings of the National Academy of Sciences of 
the United States of America 103, 11754-11759, doi:10.1073/pnas.0604744103 (2006). 
105  Chng, S. S., Ruiz, N., Chimalakonda, G., Silhavy, T. J. & Kahne, D. Characterization of 
the two-protein complex in Escherichia coli responsible for lipopolysaccharide assembly 
at the outer membrane. Proceedings of the National Academy of Sciences of the United 
States of America 107, 5363-5368, doi:10.1073/pnas.0912872107 (2010). 
106  Freinkman, E., Chng, S.-S. & Kahne, D. The complex that inserts lipopolysaccharide into 
the bacterial outer membrane forms a two-protein plug-and-barrel. Proceedings of the 
National Academy of Sciences 108, 2486-2491 (2011). 
107  Sampson, B. A., Misra, R. & Benson, S. A. Identification and characterization of a new 
gene of Escherichia coli K-12 involved in outer membrane permeability. Genetics 122, 
491-501 (1989). 115 
 
108  Braun, M. & Silhavy, T. J. Imp/OstA is required for cell envelope biogenesis in 
Escherichia coli. Molecular microbiology 45, 1289-1302 (2002). 
109  Steeghs, L. et al. Meningitis bacterium is viable without endotoxin. Nature 392, 449-449 
(1998). 
110  Moffatt, J. H. et al. Colistin resistance in Acinetobacter baumannii is mediated by 
complete loss of lipopolysaccharide production. Antimicrobial agents and chemotherapy 
54, 4971-4977 (2010). 
111  Zhang, G., Meredith, T. C. & Kahne, D. On the essentiality of lipopolysaccharide to 
Gram-negative bacteria. Current opinion in microbiology 16, 779-785 (2013). 
112  Chiu, H. C., Lin, T. L. & Wang, J. T. Identification and characterization of an organic 
solvent tolerance gene in Helicobacter pylori. Helicobacter 12, 74-81 (2007). 
113  Serina, S. et al. Scanning the< i> Escherichia coli</i> chromosome by random 
transposon mutagenesis and multiple phenotypic screening. Research in microbiology 
155, 692-701 (2004). 
114  Sperandeo, P., Pozzi, C., Dehò, G. & Polissi, A. Non-essential KDO biosynthesis and 
new essential cell envelope biogenesis genes in the< i> Escherichia coli yrbG–yhbG</i> 
locus. Research in microbiology 157, 547-558 (2006). 
115  Sperandeo, P. et al. Characterization of lptA and lptB, two essential genes implicated in 
lipopolysaccharide transport to the outer membrane of Escherichia coli. Journal of 
bacteriology 189, 244-253 (2007). 
116  Sperandeo, P. et al. Functional analysis of the protein machinery required for transport of 
lipopolysaccharide to the outer membrane of Escherichia coli. Journal of bacteriology 
190, 4460-4469 (2008). 
117  Suits, M. D., Sperandeo, P., Deho, G., Polissi, A. & Jia, Z. Novel structure of the 
conserved gram-negative lipopolysaccharide transport protein A and mutagenesis 
analysis. Journal of molecular biology 380, 476-488, doi:10.1016/j.jmb.2008.04.045 
(2008). 
118  Tran, A. X., Dong, C. & Whitfield, C. Structure and functional analysis of LptC, a 
conserved membrane protein involved in the lipopolysaccharide export pathway in 
Escherichia coli. The Journal of biological chemistry 285, 33529-33539, 
doi:10.1074/jbc.M110.144709 (2010). 
119  Chng, S.-S., Gronenberg, L. S. & Kahne, D. Proteins required for lipopolysaccharide 
assembly in Escherichia coli form a transenvelope complex. Biochemistry 49, 4565-4567 
(2010). 116 
 
120  Sperandeo, P. et al. New insights into the Lpt machinery for lipopolysaccharide transport 
to the cell surface: LptA-LptC interaction and LptA stability as sensors of a properly 
assembled transenvelope complex. Journal of bacteriology 193, 1042-1053 (2011). 
121  Gronenberg, L. S. & Kahne, D. Development of an activity assay for discovery of 
inhibitors of lipopolysaccharide transport. Journal of the American Chemical Society 132, 
2518-2519 (2010). 
122  Sherman, D. J., Okuda, S., Denny, W. A. & Kahne, D. Validation of inhibitors of an 
ABC transporter required to transport lipopolysaccharide to the cell surface in 
Escherichia coli. Bioorganic & Medicinal Chemistry 21, 4846-4851, 
doi:http://dx.doi.org/10.1016/j.bmc.2013.04.020 (2013). 
123  Sherman, D. J. et al. Decoupling catalytic activity from biological function of the ATPase 
that powers lipopolysaccharide transport. Proceedings of the National Academy of 
Sciences 111, 4982-4987 (2014). 
124  Okuda, S., Freinkman, E. & Kahne, D. Cytoplasmic ATP hydrolysis powers transport of 
lipopolysaccharide across the periplasm in E. coli. Science 338, 1214-1217 (2012). 
125  Ruiz, N., Chng, S.-S., Hiniker, A., Kahne, D. & Silhavy, T. J. Nonconsecutive disulfide 
bond formation in an essential integral outer membrane protein. Proceedings of the 
National Academy of Sciences 107, 12245-12250 (2010). 
126  Kadokura, H., Tian, H., Zander, T., Bardwell, J. C. & Beckwith, J. Snapshots of DsbA in 
action: detection of proteins in the process of oxidative folding. Science 303, 534-537 
(2004). 
127  Chimalakonda, G. et al. Lipoprotein LptE is required for the assembly of LptD by the 
beta-barrel assembly machine in the outer membrane of Escherichia coli. Proceedings of 
the National Academy of Sciences of the United States of America 108, 2492-2497, 
doi:10.1073/pnas.1019089108 (2011). 
128  Ruiz, N., Falcone, B., Kahne, D. & Silhavy, T. J. Chemical conditionality: A 
geneticstrategy to probe organelle assembly. Cell 121, 307-317 (2005). 
129  Ruiz, N., Wu, T., Kahne, D. & Silhavy, T. J. Probing the barrier function of the outer 
membrane with chemical conditionality. ACS chemical biology 1, 385-395 (2006). 
130  Srinivas, N. et al. Peptidomimetic antibiotics target outer-membrane biogenesis in 
Pseudomonas aeruginosa. Science 327, 1010-1013, doi:10.1126/science.1182749 (2010). 
131  Fischbach, M. A. & Walsh, C. T. Antibiotics for emerging pathogens. Science 325, 1089-
1093, doi:10.1126/science.1176667 (2009). 
132  Onishi, H. R. et al. Antibacterial agents that inhibit lipid A biosynthesis. Science 274, 
980-982 (1996). 117 
 
133  Barb, A. W. et al. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-
090 antibiotic activity in Escherichia coli. Biochemistry 46, 3793-3802, 
doi:10.1021/bi6025165 (2007). 
134  Ureta, A. R., Endres, R. G., Wingreen, N. S. & Silhavy, T. J. Kinetic analysis of the 
assembly of the outer membrane protein LamB in Escherichia coli mutants each lacking a 
secretion or targeting factor in a different cellular compartment. Journal of bacteriology 
189, 446-454 (2007). 
135  Silhavy, T. J., Berman, M. L. & Enquist, L. W. Experiments with gene fusions.  (1984). 
136  Kadokura, H. & Beckwith, J. Detecting folding intermediates of a protein as it passes 
through the bacterial translocation channel. Cell 138, 1164-1173 (2009). 
137  Kadokura, H. & Beckwith, J. Four cysteines of the membrane protein DsbB act in concert 
to oxidize its substrate DsbA. The EMBO journal 21, 2354-2363 (2002). 
138  Paxman, J. J. et al. The structure of the bacterial oxidoreductase enzyme DsbA in 
complex with a peptide reveals a basis for substrate specificity in the catalytic cycle of 
DsbA enzymes. Journal of biological chemistry 284, 17835-17845 (2009). 
139  Walter, T. S. et al. Lysine methylation as a routine rescue strategy for protein 
crystallization. Structure 14, 1617-1622, doi:10.1016/j.str.2006.09.005 (2006). 
140  Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227, 680-685 (1970). 
141  Malojcic, G. et al. LptE binds to and alters the physical state of LPS to catalyze its 
assembly at the cell surface. Proc Natl Acad Sci U S A (In Press) (2014). 
142  Bos, M. P. & Tommassen, J. The LptD chaperone LptE is not directly involved in 
lipopolysaccharide transport in Neisseria meningitidis. The Journal of biological 
chemistry 286, 28688-28696, doi:10.1074/jbc.M111.239673 (2011). 
143  Ujwal, R. & Bowie, J. U. Crystallizing membrane proteins using lipidic bicelles. Methods 
55, 337-341 (2011). 
144  Datsenko, K. A. & Wanner, B. L. One-step inactivation of chromosomal genes in 
Escherichia coli K-12 using PCR products. Proceedings of the National Academy of 
Sciences of the United States of America 97, 6640-6645, doi:10.1073/pnas.120163297 
(2000). 
145  Leslie, A. Integration of macromolecular diffraction data. Acta Crystallographica Section 
D: Biological Crystallography 55, 1696-1702 (1999). 
146  Evans, P. Data reduction. CCP4 Daresbury Study Weekend DL/SCI/R34, 114-122 (1993). 118 
 
147  McCoy, A. J. et al. Phaser crystallographic software. Journal of applied crystallography 
40, 658-674 (2007). 
148  Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta 
Crystallographica Section D: Biological Crystallography 67, 235-242 (2011). 
149  Van Duyne, G. D., Standaert, R. F., Karplus, P. A., Schreiber, S. L. & Clardy, J. Atomic 
structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. 
Journal of molecular biology 229, 105-124 (1993). 
150  Boggon, T. J. & Shapiro, L. Screening for phasing atoms in protein crystallography. 
Structure 8, R143-R149 (2000). 
 